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Abstract
Aging-associated vision loss is increasingly prevalent in our population and intravitreal 
injections are commonly used to administer ocular drugs to the posterior segment of the eye. 
This work aims to visualize and predict the delivery of ocular drugs by combining micro- 
computed tomography (micro-CT) imaging and computational fluid dynamics (CFD) 
modeling. Intravitreal injections were administered into ex vivo porcine eyes and imaged for 
an extended period of time to track the progression of the injected drug mimic. Non-invasive 
imaging allowed for precise determination of contrast agent concentration, flow patterns and 
fate. A computational model was developed that provided quantitative agreement with the 
concentration values found in the experimental study and allowed for easy manipulation of 
parameters. The ability to accurately model drug transport following an intravitreal injection 
provides vital information to better understand the specific concentration and time frame for 
the drug to reach the target site.
Keywords: intravitreal injection, drug delivery, vitreous, diffusion, micro-computed 
tomography, computational fluid dynamics
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Developing greater insight and understanding into the processes involved in ocular drug 
delivery, particularly in the posterior segment o f  the eye, is vital information when 
developing drugs and drug delivery systems. This chapter provides the motivation o f  the 
work to be presented and background o f  eye anatomy, ocular drug delivery, imaging 
modalities and computational flu id  dynamics. An outline o f  the hypothesis, objectives and 
experimental design provide the rationale o f  what will be presented in the following 
chapters.
1.1 Background and Motivation
Every 12 minutes someone in Canada develops significant vision loss. Vision loss 
accounts for the highest health care costs compared to any other disease in Canada, 
including diabetes, cardiovascular disease and cancer.1 The leading cause of vision loss 
and legal blindness in people over the age of 50 in the developed world is age-related 
macular degeneration (AMD).2,3 AMD is a chronic degenerative disease that affects a 
small area at the back of the eye called the macula and it is this region of the eye that is 
responsible for central vision. Advanced stages of AMD cause complete loss of central 
vision, while some peripheral vision is maintained. A person’s quality of life is 
significantly reduced when affected by vision loss, such as AMD.4'6 AMD and other 
ocular diseases associated with the posterior segment of the eye, such as diabetic 
retinopathy, macular edema and retinal vein occlusion, are commonly treated by 










Figure 1.1 Anatomy of a normal human eye.
Adapted from: National Eye Institute, National Institutes of Health.
1.1.1 Eye Anatomy
Important anatomical features of the human eye for the purpose of this work are shown in 
Figure 1.1. Ocular anatomy is typically divided into two groups: anterior and posterior. 
The anterior region encompasses the region between the cornea and the lens. The cornea 
is the outermost layer of the anterior segment of the eye and is most useful in orienting 
the front of the eye. Light first passes through the cornea and then the lens, which focuses 
the light onto the back of the eye, specifically the retina. The posterior region includes the 
sclera, vitreous and retina The sclera is the white covering of the eye that acts as a 
protective layer and helps maintain the shape. Within the eye is the vitreous cavity which 
contains the vitreous body (or humor), a jelly-like substance. The vitreous is enclosed by 
a membrane called the hyaloid membrane. The anterior hyaloid membrane separates the 
vitreous from the anterior chamber and the lens. An important function of the vitreous 
body is to hold the retina against the back of the eye. The retina is a very thin multi-layer 
o f cells at the back of the eye that is responsible for detecting the light and transmitting 
the image to the brain via the optic nerve. The small specialized region of the retina
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responsible for detailed central vision, called the macula, is located near the center of the 
retina. At the center of the macula is the fovea, where the highest density of 
photoreceptor cells are found and our sharpest and most brilliantly coloured vision 
occurs.
1.1.1.1 Vitreous Body
The adult human vitreous has a length (from back of lens to retina) of around 16.5 mm, 
weighs approximately 4 grams, and occupies a volume of about 4 ml. The primary 
structural components, type II collagen and hyaluronic acid, occupy less than 1% of the 
total volume of the vitreous. The rest of the vitreous is composed of water. The 
chemical composition of a typical human vitreous and the distribution of these 
components are not homogenous.10 The mature vitreous is a transparent gel with 
viscoelastic rheological properties. Rheological values for human vitreous have been 
shown to be a function of region. The normal human vitreous has a density close to that 
of water (1 g/ml) and a kinematic viscosity of approximately 1.41 O'4 m2/s. The normal 
postnatal vitreous is a homogenous gel and the fundamental aging process consists of a 
progressive disintegration of the gel structure, particularly at the center of the vitreous.11 
This process is termed vitreous liquefaction and starts early in life. Liquefied vitreous has 
a viscosity closer to 10' m /s. The large volume and gel structure of the vitreous, 
consisting of several large molecular weight polymeric elements, suggests that its 
function is to provide a system that absorbs mechanical stress and protects the 
surrounding tissues during eye movement and physical activity. The vitreous 
accomplishes its mechanical function by securing the retina’s adherence to the outer 
layers and filling up the vitreous chamber, and acting as a barrier between the anterior
n
and posterior segments of the eye for heat and drug transport.
There are several vitreous factors that affect the success or failure of drug delivery in the 
eye. The vitreous body is relatively inert connective tissue and is quite porous and thus 
transmits the pressure from the anterior chamber throughout the interior of the eye.12 It 
has been observed that a needle hole in the sclera can affect transport between the
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aqueous and vitreous bodies.13 Many existing works consider diffusion to be the greatest 
contributing factor to drug flow in the vitreous,14’15 over other transport mechanisms such 
as convection. The degree to which convection is responsible has been shown to vary 
with drug size and eye species. ’ An important factor to consider when dealing with 
elderly patients is that their vitreous will be liquefied to some extent and may be less 
efficient as a transport barrier.11
1.2 Ocular Drug Delivery
Drugs can be introduced into the eye by a variety of routes. The regions to which delivery 
of the drug is targeted and in which it is administered are divided in the same way as the 
eye is anatomically, into anterior and posterior. Drug delivery to the anterior region is 
typically administered by topical eye drops or subconjunctival injection and used to treat 
diseases such as glaucoma, infection and inflammation. Administration of drugs to the 
posterior region is accomplished using systemic administration, topical delivery and 
direct injection. Diseases that require administration of drugs to the posterior segment 
include AMD, diabetic retinopathy and uveitis.
Drug delivery in the eye poses a number of challenges including, but not limited to, 
corneal barrier, high aqueous humor turnover, blood-aqueous barrier and blood-retina 
barrier.19 Significant work has been devoted to developing and improving drug delivery 
systems for the eye. Methods that have been developed recently, but not yet common in 
clinical practice, include intraocular implants, sustained release biodegradable
01 00 04implants, micro- and nanoparticle extended-release drugs ' and implantable 
intraocular pumps. These remain as potential options in future clinical use, but all rely 
on the transport properties of drug flow in the vitreous. Combined with this reason and 
that intravitreal injections are currently very common in the clinic, intravitreal injections 
will be the route of choice in this study’s experimentation.
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1.2.1 Intravitreal Injections
The first choice for administering drugs to the posterior segment of the eye is via 
intravitreal injections. Intravitreal injections are a direct needle injection into the eye 
through the region called the pars plana, where the cornea meets the sclera. The drug is 
administered into the human vitreous in volumes of 30-100 pi. This volume of drug is 
expected to reach the target site, commonly the retina, by means of diffusion and 
convection. It has been estimated that intravitreal drug transport in humans is composed 
of 30% convective flow and the remainder diffusive flow.16 The challenge of intravitreal 
injections is due to the large diffusion distance in which the drug must travel. When 
administering a small volume of drug in a relatively large region, the challenge becomes 
the delivery of sufficient drug concentration to the correct region. The desirable fate of 
the drug is to be present at the target site, specifically the macula in treatment of AMD, at 
a therapeutic level of concentration for a sufficient time period without reaching levels of 
toxicity.27,28
Intravitreal injections remain the most commonly used method of administering drugs to 
the posterior segment of the eye. Despite the invasive nature of the injections there is a 
low rate of complications, such as inflammation, cataract and retinal detachment, that 
result.29,30 The number of intravitreal injections being completed in Canada has increased
dramatically since 2003. In Ontario between 2005 and 2007, the rate of intravitreal
•2 1
injections grew 8-fold from 3.5 to 25.9 injections per 100 000 patients per month. This 
has been attributed to the increased development of intraocular drugs, specifically those 
for the treatment of AMD.
1.2.2 Drugs Administered by Intravitreal Injection
Recent development of drugs for intravitreal injection have provided a variety of 
treatment options for diseases such as AMD. Each drug has unique properties, such as 
molecular weight, that may affect its transport properties in the vitreous. Table 1.1 lists 
the drugs used in the treatment of AMD via intravitreal injection and characteristics 
found in the prescribing information sheets.
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Intravitreal injection volumes and doses administered in humans for the treatment of 
AMD range considerably between drugs. Taking into account the typical volume of 
vitreous in humans, this translates into a large difference in the concentration, from 3.47 
to 25 mg/ml, in which the drugs listed in Table 1.1 are administered. The ability to 
optimize this concentration is vitally important in order to be effective in treating the 
disease while not reaching levels of toxicity.
Table 1.1 Age-related macular degeneration drugs
Characteristics of drugs used in treatment of age-related macular degeneration 












(Macugen®)32 50 90 3.47 0.3
Bevacizumab
(Avastin®)33 149 50 25 1.25
Ranibizumab




110 - - 0.5-2
*Aflibercept (VEGF Trap-Eye, Regeneron Pharmaceuticals Inc) is currently in clinical trials for 
the treatment of AMD, diabetic macular edema and central retinal vein occlusion and specific 
prescribing information is not yet available
1.3 Imaging
With the development of specialized imaging modalities such as molecular imaging, 
optical coherence tomography, positron emission tomography, magnetic resonance 
imaging (MRI) and micro-computed tomography (micro-CT), we are now able to non- 
invasively gain detailed information from biological systems. All modalities are useful 
tools in retrieving data on drug delivery, distribution and elimination. MRI is particularly 
useful for soft tissue imaging, but has limitations of low spatial resolution and long scan 
times,35,36 which are both very important components when studying ocular drug
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delivery. In this study, micro-CT was chosen as the non-invasive imaging modality for 
tracking drug delivery in the eye for its high spatial resolution and fast scan time.
1.3.1 Micro-Computed Tomography
Micro-CT is an x-ray based imaging system that combines x-ray transmission with 
computed tomographical reconstruction to provide three-dimensional (3D) image 
volumes. An x-ray source transmits a beam of photons through the specimen and 
generates a set of 2D radiographs. These 2D radiographs are reconstructed into grey-scale 
images that are based on the tissue electron densities and level of photon absorption. 
The set of 2D images are further reconstructed into a 3D volume for further analysis. CT 
contrast is achieved though the difference of the x-ray photon attenuation between 
materials. Attenuation is the decrease in the number of photons as the x-ray beam passes 
through material as a result of scattering or absorption. Heavy elements have a high 
attenuation primarily due to the absorption of the x-ray photons while soft tissue has a 
low attenuation due to the transmission of x-ray photons through the material. 
Attenuation therefore leads to image contrast in CT imaging.
For the purpose of this study, the delineation of anatomical features is not as important as 
visualizing the injected drug mimic. Major anatomical features such as the cornea, lens 
and sclera were all visible in the reconstructed CT images and provided useful landmark 
information. Radiopaque contrast agents with high atomic number and density, 
characteristics of high attenuation, were chosen to be used as drug mimics for clear 
differentiation from surrounding tissue and background. Specific concentrations can be 
measured by taking advantage of the linear relationship between attenuation and contrast 
agent concentration in x-ray imaging and is the basis of this study.38,39 Micro-CT has 
been shown to have the capabilities in providing advanced analytical techniques and 
detailed internal quantitative information to investigate drug delivery.40
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1.4 Computational Fluid Dynamics
Computational fluid dynamics (CFD) is a method of modeling fluid transport using 
numerical analysis. CFD is made up of three different disciplines: engineering (fluid 
dynamics), mathematics and computer science.41 Fluid dynamics encompasses the study 
of fluids either in motion or at rest and how they interact with other processes such as 
heat transfer and chemical reactions. Transport properties (i.e. diffusion coefficient, 
density, viscosity) are used to describe the fluid under study within the simulations in the 
mathematical equations. The mathematical equations are used to describe the fluid’s 
characteristics, such as concentration and flux, based on the transport properties input 
into the equations. It is the computational aspect that combines it all together into an 
efficient software package.
The use of CFD for modeling ocular drug flow provides the capability to manipulate a 
variety of transport properties and investigate the extent to which they are important in 
the mechanisms of drug delivery. All of this can be completed without the use of animals 
or humans and allows for a cost-effective method of studying ocular drug flow. However, 
it is important to develop a CFD model that is based on experimental evidence and can be 
validated. With a physiologically relevant model, realistic predictions can be made by 
running a simulation and provide insight into ocular fluid dynamics that may not be 
realized in any other way.15
1.5 Objectives
The global objective of this work is to gain a better understanding, through the 
integration of imaging and modeling, of drug distribution and fate in the eye when 
administered to the posterior segment
The specific objectives are:
• To compare the x-ray compatibility and transport properties of contrast 
agents, acting as drug mimics, in the vitreous body of the eye.
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• To characterize and understand the transport properties of a drug mimic in 
the vitreous body using micro-computed tomography imaging.
• To examine any unexpected characteristics arising from intravitreal 
injections that could impact ocular drug delivery.
• To develop a computational fluid dynamics model based on data from 
micro-computed tomography images.
1.6 Hypotheses
Transport properties will vary between contrast agents due to differences in molecular 
weight and will be able to be visualized and calculated using image analysis of micro-CT 
images. Imaging of the eyes before, after, and in some cases during injection, will allow 
for full assessment of the injection outcomes and reveal details of any potential 
complications. Computational fluid dynamics will provide a time dependent model of 
drug flow in the vitreous with concentration profiles that reflect those of the ex vivo 
imaging results.
1.7 Experimental Design
X-ray compatibility and transport properties will be assessed using micro-CT imaging. 
Measures of signal intensity, clearing time and diffusion coefficients will be analyzed and 
compared between differing contrast agents and concentrations. The iodinated contrast 
agent will be studied as a possible drug mimic and the gold nanoparticles will be studied 
as a drug mimic and as a drug tag. It is expected both contrast agents will provide 
visualization within the vitreous, but the transport properties, such as the diffusion 
coefficient, are expected to differ due to the material properties, such as the large 
difference in molecular weight between the two agents.
Micro-CT will allow for non-invasive analysis of an injected bolus of the drug mimic 
over an extended period of time. Each eye will be monitored for the full duration of the
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scanning, providing a complete temporal data set per eye. Calculation and analysis of the 
diffusion coefficient will be completed and will be instrumental in understanding the 
mechanisms of diffusion in intravitreal drug transport.
Anomalous features have the potential to impact ocular drug delivery. Some 
characteristics not expected to be seen following an intravitreal injection are identified 
and analyzed. Air bubbles and their fate within the vitreous, needle tip movement during 
the injection resulting in an altered bolus shape and jetting from the tip of the needle, can 
all impact the transport of drugs in the vitreous. A better understanding of how they may 
influence drug flow and possible ways to eliminate them will be identified in an effort to 
optimize intravitreal injection techniques.
Utilizing the data acquired from non-invasive imaging, a computational fluid dynamics 
model is developed based on experimental results. Using the knowledge from the micro- 
CT experiments with that of the literature, a model of drug flow in the vitreous can be 
used to complete theoretical studies using different drug properties and eye parameters. It 
is expected the computational fluid dynamics model will provide strong correlation to the 
experimental results and allow for validation of the model. The combination of non- 
invasive imaging and computational fluid dynamics provides a unique combination of 
resources to study drug distribution and fate in the eye. Combing these methods with 
what is currently known of intravitreal injections and associated drugs, new methods and 
tools can be developed for studying intravitreal drug delivery.













Figure 1.2 Experimental design flow chart
The general study design to address the objectives presented and create a link between 
non-invasive micro-CT imaging data and computational fluid dynamics modeling in 
shown in this flow chart.
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Chapter 2
2 Comparison of radiographic contrast agent drug mimics 
in the vitreous
The purpose o f  the work presented in this chapter is to compare the x-ray compatibility 
and transport mechanisms o f  two contrast agents acting as drug mimics. Iodine based 
(Omnipaque™) and gold nanoparticle (AuroVist™) contrast agents were studied using 
micro-CT imaging. Comparisons o f  signal intensity, dilution in the vitreous and 
molecular weight are made to demonstrate their effectiveness in use as an intravitreal 
injection drug mimic or agent acting as a tag fo r a clinical drug.
2.1 Introduction
With an increasing number of intravitreal injections being administered1 and more drugs 
being developed for use in the vitreous of the eye, there is a requirement to know the flow 
and fate patterns of these drugs. In studying ocular drug transport, it is vitally important 
to maintain the integrity of the eye and not disrupt its normal state. Non-invasive imaging 
is appropriate since it allows for each specimen to be used for its own control and can be 
longitudinally monitored.2 This has been recently made possible with the development of 
non-invasive imaging techniques, such as micro-computed tomography (micro-CT). 
Micro-CT provides high resolution volumetric images, but provides poor soft tissue 
contrast. This limitation can be overcome using contrast-enhanced imaging to 
successfully visualize the transport of an injected solution.
An injected contrast agent can be utilized to achieve higher contrast within a CT image. 
Materials that have a higher atomic number (Z) have a higher contrast in x-ray imaging. 
Iodine (Z = 53) is a commonly used material as a radiographic contrast agent. Iodine’s 
high atomic number means it is a heavy element and therefore has a higher attenuation 
coefficient. Iodinated solutions are an ideal contrast agent for clinical applications
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because they are water soluble making them highly compatible with biological systems. 
Gold nanoparticles have recently become available as a new x-ray contrast agent. Gold 
has a higher atomic number (Au 79 vs. I 53) and a higher absorption coefficient (at 100 
keV: gold 5.16 cm2/g; iodine 1.94 cm2/g; soft tissue 0.169 cm2/g). This has been shown
•5
to account for about 3 times greater contrast per unit of weight of gold than iodine.
Drug administration via intravitreal injection relies on the assumption that the injected 
drug will diffuse to the target site within the eye, rather than being injected at the exact 
site. This is the case since the target site is very delicate retinal tissue and is a very small 
location (5-6 mm macula diameter in humans). Since the drug must travel through the 
vitreous to the target site, it is important to be able to visualize the contrast agent post­
injection within the eye for several hours. Long scan times require a contrast agent that 
will persist at a sufficient level of concentration to be imaged for the duration of the 
entire study. It is also important to keep the intravitreal injection clinically relevant and 
therefore at a volume that resembles that used clinically, which is approximately 50-100 
pi for the human eye.4
Previous work has shown magnetic resonance imaging (MRI) can be used to monitor
r  n
ocular drug delivery using compatible contrast agents. ' MRI contrast agents used in 
previous studies include manganese ion (Mn j ,  Mn with ethylenediaminetetraacetic 
acid (EDTA) chelate and gadolinium-diethylenetriaminopentaacetic acid (Gd-DTPA). 
Mn2+ and MnEDTA2" are both small ions that would have very different transport 
properties than macromolecules. Gd-DTPA is a macromolecule that should more closely 
represent the flow characteristics of drugs used in intravitreal injections. MRI studies are
limited in that the spatial resolution may not be high enough to determine the
8concentration or small volume of drug surrogates in thin tissues less than 0.3mm.
This study utilizes a non-invasive imaging modality that allows for rapid scan time and 
high resolution. The purpose of this work is to compare the x-ray compatibility and 
transport mechanisms of contrast agents acting as drug mimics as they flow through the 
vitreous body of the eye. This is accomplished by the objectives of this work which are to 
determine if gold nanoparticles are a useful radiographic contrast agent for visualizing an
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injected bolus within an eye over time and to determine the optimal range of 
concentrations to use for intravitreal injections when studying drug transport and flow in 
the eye.
2.2 Materials and Methods
2.2.1 Micro-Computed Tomography
Micro-computed tomography (micro-CT) scanning was performed using a pre-clinical 
system (eXplore Locus Ultra, General Electric Healthcare Bioscience, London, Ontario, 
Canada). The system provides the fast-scanning speed of a clinical scanner with the high 
resolution of micro-CT and is designed for small animal experiments. It is this system 
that will be utilized in future ex vivo and in vivo experiments looking at drug delivery in 
the eye. A flat-panel detector mounted on a slip-ring CT gantry was used to acquire 3D 
volumetric data in 8-16 seconds with an isotropic spatial resolution of 150 pm. The x-ray 
tube voltage and beam current were kept constant during the experiments at 80 kVp and 
the 80 mA, respectively.
2.2.2 Contrast Agents
Two commercially available contrast agents were chosen for this study. Iodine based 
iohexol (Omnipaque™ 300, GE Healthcare, Oakville, Ontario, Canada) was chosen 
because of its common use as a radiographic contrast agent both clinically and 
experimentally and is very economical. Omnipaque 300 contains 300 mg of iodine per 
milliliter and has the molecular weight of 821 g/mol. It has an osmolarity of 465 
mOsm/L, absolute viscosity of 6.3 at 37°C and specific gravity of 1.349 at 37°C.
Gold nanoparticles (AuroVist™ 1102, Nanoprobes Inc, Yaphank, New York, USA) were
•5
chosen as they have been shown to provide higher contrast at lower concentrations. The 
molecular weight of gold nanoparticles is much higher than iodine (50 kDa vs. 0.82 kDa) 
and studies have shown this to attribute to a slower clearing time in biological systems.3 
This provides for a longer period of contrast detection at a lower initial concentration. In
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addition, the 1.9 nm gold nanoparticles have a similar molecular weight as the most 
common anti-VEGF drugs used to treat AMD.
2.2.2.1 Iodine and Gold Concentration Standards
Concentration standards were made using vials of varying iodine concentrations. 
Solutions were prepared in the following concentrations: 300, 150, 75, 37.5, 18.75 and 
9.375 mg/ml. The 300 mg/ml sample was full strength Omnipaque 300. The 150 mg/ml 
solution was prepared by diluting 100 pi of full strength Omnipaque 300 with 100 pi of 
Phosphate Buffered Saline (PBS) lx  concentration. To prepare the 75 mg/ml solution 25 
pi of Omnipaque 300 was diluted with 75 pi of PBS, the 37.5 mg/ml solution was 12.5 pi 
Omnipaque to 87.5 pi PBS, the 18.75 mg/ml solution was 6 pi Omnipaque to 94 pi PBS 
and the 93.75 mg/ml solution was 3 pi Omnipaque to 97 pi PBS. Two additional vials of 
deionized water and air were included to assist with signal intensity calibration.
For concentration standards of gold nanoparticle solutions were prepared in the following 
concentrations: 200, 134, 67, 33.5, 16.75 and 8.375 mg/ml. The 200 mg/ml solution was 
prepared by diluting the 40 mg vial of gold nanoparticle powder with 200 pi of PBS. The 
134 mg/ml solution was prepared by taking 100 pi of the 200 mg/ml solution and diluting 
it with 50 pi of PBS. This 1:1 dilution process was repeated to make the remaining 
concentration solutions. Two additional vials of deionized water and air were included to 
assist with signal intensity calibration.
2.2.3 Intravitreal Injections
Freshly harvested enucleated porcine eyes were obtained from a local abattoir and used 
within 10 hours postmortem. During scanning and for the remainder of the study, they 
were maintained at 24°C (+/- 2°C). Pre-injection scans confirmed no abnormalities in any 
eyes. Iodinated and gold nanoparticle contrast agents were used as drug mimics at 
varying concentrations. Clinically relevant intravitreal injections of a 30 pi volume of 
contrast agent were administered into 24 enucleated eyes. The injection volume of 30 pi 
was calculated based on the smaller vitreous volume of the pig eye compared to that of 
the human. Injections were performed 2-3 mm posterior to the superotemporal limbus at
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a depth of 1 cm using 29-gauge needles (SS05M2913, Terumo Medical Corporation, 
Somerset, NJ, USA).
2.2.4 Imaging
Scans were acquired up to 230 minutes (the anticipated time for the contrast agent to 
remain at sufficient concentration and/or reach the retina) following the injection to allow 
for visualization of the contrast agent’s progression through the vitreous. Concentration 
standards were included in the scans for calibration purposes.
2.2.5 Image Analysis
3D computed tomography visualization and analysis software (MicroView 2.1.2, GE 
Healthcare, London, Ontario, Canada) was used to analyze the reconstructed CT images. 
The CT number and standard deviation for each concentration sample in the 
concentration standards were recorded. Measurements were taken from the center of each 
vial in a 2 x 2 x 2 mm region of interest and recorded in Hounsfield units (HU). Linear 
regression analysis was used to determine the relationship between signal intensity and 
contrast agent concentration. This was completed for both iodine and gold nanoparticle 
samples.
2.2.6 Estimation of Diffusion Coefficients
The diffusion coefficient of Omnipaque™ in the vitreous was estimated using the Wilke- 
Chang correlation,9 since that value was not available from published literature. An 
estimate was made based on Gd-DTPA, which has a similar molecular weight (936.0 
g/mol vs. 821.1 g/mol). The diffusivity of Gd-DTPA in water is known to be 2.6><1 O'10 
m2/s.10 The following correlation equation can be derived if it is assumed that the molar 










which yields 2.8X 10’10 m2/s for Omnipaque in water. Since the vitreous is composed of 
more than 99% water,12 this assumption was thought to be reasonable.
There is no empirical data to date for the diffusion coefficient of gold nanoparticles 
(AuroVist™ 1.9 nm). Since the particles are close to spherical and are much larger than 






where R is the gas constant (8.3145 J/mol K), T is the absolute temperature (room 
temperature = 295 K), Z is the viscosity of the diffusing medium (0.001002 kg/m s), r is 
the radius of the diffusing particle (1.5 nm) and N  is Avogadro’s number (6.0221x 1023 
per mole). The calculated value for 1.9 nm gold nanoparticles in water is 1.44x10' m /s 
with the assumption no aggregation occurs. This will be used as a comparison value to 
those calculated for gold nanoparticles in the vitreous.
2.3 Results
2.3.1 Calibration
Calibration of the signal intensity with contrast agent concentration was determined using 
the standards of various concentrations. The concentrations of both iodine 
(Omnipaque™) and gold nanoparticles (AuroVist™) along with air and deionized water 
are shown in Figure 2.1.
22
Omnipaque





134 67 33.5 16.75 8.38 Air Water
•
Figure 2.1 Vials of contrast agents containing varying concentrations
Reconstructed CT image of the calibration standards with vials of iodine (Omnipaque) in 
the following concentrations 300, 150, 75, 37.5, 18.75, 9.38 mg/ml and gold 
nanoparticles in the following concentrations 200, 134, 67, 33.5, 16.75, 8.38 mg/ml. 
Vials of air and deionized water were also included with each sample for CT number 
(HU) calibration.
The signal intensity, CT number (HU), is shown as a function of contrast agent 
concentration (mg/ml) in Figure 2.2 for both iodine and gold nanoparticles. Linear 
regression results for iodine can be expressed as an equation 5  = 31.9 ml/mg x C, + 956.0 
HU, where S  is the signal intensity and C, is the iodine concentration in mg/ml (r2 = 
0.9892). For gold nanoparticles the result of linear regression is S  = 31.0 ml/mg x Cg + 
61.1 HU (r2 = 0.9993), where Cg is the gold nanoparticle concentration. These results are 
indicative of a highly linear system (p < 0.01 and p  < 0.0001, respectively). The y- 
intercept is expected to be zero and for both contrast agents it was significantly different. 
This was also reported by Du et al. that indicated the micro-CT scanner calibration may 
need to be adjusted,14 but does not impact the results presented herein as our custom 
concentration standards were used for calibration of the CT number with contrast agent 
concentration.
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Figure 2.2 CT number and concentration calibration plot
Plot of measured CT number (signal intensity) versus known contrast agent 
concentrations (circles, iodinated Omnipaque™; triangles, gold nanoparticle 
AuroVist™). Linear regression results indicate a significant correlation is seen between 
signal intensity and concentration for both contrast agents.
Calibration findings were compared to that of a study performed using the same micro- 
CT scanner and a custom made multiple parameter quality assurance phantom.14 The 
linearity of the system was comparable between the two studies as all cases of 
concentration standards exhibited strong linear regression. Measurements of signal 
intensity in the water and air samples provided values shown in Table 2.1.
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Table 2.1 Comparison of CT numbers for air and water
Measured CT numbers (HU) and standard deviation (HU) of water and air used in the CT 
calibration standards compared between previous studies (Du et al. 2007) and those used 
in the current work.
Material
Measured CT Numbers ± SD
Du et al. 2007 lohexol Standards Gold Nanoparticle 
Standards
Water -7 ±51 91 ±22 103 ±23
Air (central) -909 ± 48 -1001 ±23 -1003 ±22
Air (peripheral) -1003 ± 35
2.3.2 Contrast Dilution
The contrast agent in the eye was evalutated to determine if it was present at a sufficient 
concentration to be detected for an extended period of time. Iodine solutions and gold 
nanoparticles were monitored for up to 230 minutes at varying concentrations. The same 
sagittal plane images of two specimens, one with an injection of iodine solution and one 
with an injection of gold nanoparticles, were compared at the time points 8, 35, 195 
minutes (Figure 2.3). Despite a small difference in initial concentration (37 mg/ml vs. 25 
mg/ml) both specimens exhibited similar visualization of concentration at the respective 
time points.
Quantitative analysis was completed using measured signal intensity values taken from 
scans at each time point. The results are shown in Figure 2.4 with the maximum 
detectable signal, representing the concentration within the scan, plotted against time. 
Various concentrations were plotted to determine how the clearing profiles differed 
between concentrations. The background signal in the image from vitreous had a mean of 
210 ± 65 HU and was included in the graph. The iodine and gold nanoparticle solutions 
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Figure 2.3 CT scan slices showing contrast agent in vitreous at time steps
Comparison of reconstructed micro-CT images taken in the same plane (sagittal) and 
location at time points 8, 25 and 195 minutes between iodine based Omnipaque™ (37 
mg/ml) and gold nanoparticle based AuroVist™ (25 mg/ml) indicates there is very little 
difference in visualization of contrast between the two.
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Time (seconds)
Figure 2.4 Contrast agent dilution from the vitreous graphed over time
Comparison of contrast agent dilution within the vitreous based on the maximum 
detectable pixel value (HU) at each time point indicates iohexol (Omnipaque™) and gold 
nanoparticles (AuroVist™) follow different trends.
2.3.3 Molecular Weight
The molecular weight of the contrast agents and common intravitreal drugs were 
compared alongside calculated diffusion coefficients (Table 2.2). Molecular weight 
values were taken from product literature and diffusion coefficients were calculated 
experimentally or taken from literature. Figure 2.5 shows the diffusion coefficients on a 
logarithmic scale as a function of the molecular weight. The linear regression result is 
also shown with the equation log(D) = -4.99xl0'3 1/kDa x MW+ 0.27 cm2/s (r2 = 0.674). 
This shows that there is not a very strong linear relationship for the data points used, but 
the values do lie within the 95% confidence interval.
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Table 2.2 Comparison of molecular weight and diffusion coefficient values
Diffusion coefficient values of Omnipaque™ and AuroVist™ are based on and 





















a Wilke-Chang estimation 
b Stokes-Einstein estimation
c From Molokhia et al. using free aqueous diffusion coefficient estimation 
d From S.K. Li et al. using dynamic light scattering measurements at 25°C
Figure 2.5 Diffusion coefficient and molecular weight linear regression
The relationship between diffusion coefficient (cm2/s) and molecular weight kDa) using 
values from Table 2.2, r2 = 0.674. Dashed lines indicate 95% confidence interval.
28
2.4 Discussion
Both contrast agents provided statistically significant linearity (p < 0.01) in signal 
intensity and concentration analysis, as was expected and shown in previous work.14 
Calibration is an important quality assurance step to the analysis of contrast agents, 
especially when concentration information will be derived from the scans. It is also 
vitally important not to rely on the same results for each successive scan (whether on the 
same day or not). A simple and useful approach to receiving calibration information with 
each scan is to include samples of diluted contrast agent vials, as was completed in this 
study, with the specimen of interest and in the scanner’s field of view. The vials that were 
made up for this study will be used in successive experiments looking at drug transport 
following porcine eye injections.
The iodine and gold nanoparticle solutions can be detected at concentrations of 9 mg/ml 
and 3 mg/ml and greater, respectively, in the porcine eye. This is calculated using the 
upper limit of the 95% confidence interval of the background (vitreous) and allows for 
clear differentiation. Similar results were achieved of significantly higher contrast from 
gold nanoparticles compared to iodinated solutions when equivalent molar concentrations 
were used.15 To be able to visualize the contrast agent in the eye for a period of time, a 
higher concentration would be required. The minimum concentration required is 
dependent on the time in which one wishes to visualize the contrast agent. However, 
Figure 2.4 provides useful information in determining this information and can be used as 
a reference when choosing the initial concentration of the drug surrogate to inject into the 
eye. One could use a significantly higher concentration to be confident sufficient contrast 
is achieved, but when using a costly compound, such as gold nanoparticles, it is desired 
to use the minimum amount necessary.
The most notable difference was that the gold nanoparticles rate of dilution was lower 
than that of the iodine. This allows for lower concentrations of gold to be used in order to 
obtain the same degree of signal intensity higher iodine concentrations would achieve. 
This appeared to be in part due to the larger molecular weight of the gold nanoparticles 
(50 kDa for gold nanoparticles vs. 0.82 kDa for iodine), since they do not move through 
the vitreous as quickly. This observation has been shown before in pharmacokinetic
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studies.16,17 This is an important characteristic to point out as the molecular weight of 
gold nanoparticles is the same or very similar to intravitreal drugs. Therefore, gold 
nanoparticles acting as a drug surrogate provide a more representative example of how an 
intravitreal drug such as Macugen® or Lucentis® would be transported in the eye. A 
comparison of the molecular weight, typical injection volume, concentration and dosage 
between surrogate contrast agents used in this study and common AMD drugs are 
described in Table 1.1.
Gold nanoparticles allow for tagging to other agents, such as fluorescein and anti-bodies. 
This provides greater capabilities in that multiple imaging modalities could be used to 
investigate the drug flow, such as fluorescence microscopy or molecular imaging.3 
Custom contrast agents could be developed where the gold nanoparticles are bound to an 
ocular drug (ex. anti-VEGF) that would target the site of retinal disease (ex. macula). 
Gold is available in a variety of sizes and forms, which would influence the visualization 
and clearing properties. This also provides greater options in choosing a drug surrogate 
and matching the properties to a specific drug.
A limitation of this work is the assumption that the contrast agents used act in the same 
way as ocular pharmaceutical drugs used clinically. This was addressed by finding a 
solution that was comparable in molecular weight to the most commonly used AMD
drugs. Molecular weight is only one pharmacokinetic property of a drug that may affect
1 8its relationship with the vitreous, others include surface chemistry and drug elimination. 
Since these findings are being used to investigate drug flow through the vitreous and 
molecular weight has been shown to be a major influence on the drug’s elimination from 




The necessary concentration and signal intensity information has been obtained allowing 
for a direct comparison of iodine and gold nanoparticle solutions. It has been shown gold 
nanoparticles have the ability to sustain contrast over an extended period of time, can be 
used at lower concentrations than iodinated contrast agents, and closely resemble the 
ophthalmological drug’s molecular weight. However, both iodine and gold nanoparticle 
contrast agents can be successfully used to track a bolus through the vitreous and permit 
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Chapter 3
3 A framework for modeling ocular drug transport and 
flow through the eye using micro-CT
This chapter describes the experimental design and analysis o f  micro-CT imaging data 
fo r  assessment o f  concentration and transport mechanisms o f  ocular drug mimics 
following intravitreal injection. Diffusion coefficients o f  the injected iodine and gold 
nanoparticle solutions were estimated using non-linear regression analysis with a 
diffusion model. There was a predominantly diffusive component in the movement o f  the 
contrast to the back o f  the eye in the horizontal (sagittal & coronal) directions, with 
ultimate retinal fa te  observed after 120 minutes. A real-time, accurate, non-invasive 
method o f  tracking a bolus and its concentration was achieved using a high spatial 
resolution and fast scanning speed micro-CT system.
3.1 Introduction
In a clinical environment, ocular drugs are often delivered topically as an aqueous eye 
drop solution or by direct intravitreal injection. These delivery methods are inherently 
pulsed with a short period of overdosing followed by a long period of underdosing.1 As 
many drugs have a narrow therapeutic window of effectiveness and may be toxic at 
higher concentrations,2 the ability to predict local drug concentrations is necessary for 
proper loading of the delivery system. However, it has proven difficult to track and 
predict drug flow and fate in vivo. Many drug delivery strategies are accepted because of 
proven efficacy and an acceptable incidence of complications, but not based on a 
thorough knowledge of the specific pharmacokinetic properties of the eye and so
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potentially remain under-optimized. Though there is ample evidence to indicate that the 
various therapeutic agents administered via intravitreal injection have an effect at the 
retina,4'7 the details of drug delivery, transport and fate remain elusive. While there are
o
complications associated with intravitreal injections, it remains the route of choice for 
administering certain therapeutic agents.9,10
The distribution of injected compounds in the vitreous has been studied both theoretically 
and experimentally.11' 14 The first study to show experimentally measured concentration 
distribution in the vitreous assessed the concentration of various injected fluorophores in 
frozen sections of the vitreous.11 This model included examination of the effects of 
intravitreal injection position and volume.15 Pharmacokinetic analyses of intravitreal 
injections using bevacizumab (Avastin®) and ranibizumab (Lucentis®), two common 
vascular endothelial growth factors (VEGF) inhibitors, have been conducted in rabbit 
eyes.16,17 These studies involved euthanization of rabbits at various time points following 
drug injection and measurement of drug concentrations in the aqueous fluid, whole 
vitreous and serum. While such pharmacokinetic studies have yielded important 
information, they provide little understanding of drug transport mechanisms through the 
vitreous and retinal drug concentrations. A recent technique to examine molecular tracer 
distribution in the vitreous involves snap freezing the whole globe to isolate the vitreous 
after superficial thawing.18 This approach provides more information regarding vitreal 
transport kinetics, but remains limited since it requires enucleation and significant eye 
processing prior to drug transport assessments.
The techniques presented above have several important limitations. Those which involve 
the use of fluorophores or dyes have the disadvantage of requiring enucleation for 
analysis to re-enact the movement of the substance in vivo. Most importantly, these 
approaches also prevent real time or serial time point studies, and are unable to provide 
drug transport gradients from the eyes of individual animals.19 Magnetic resonance 
imaging (MRI) has been used to monitor the movement of a contrast agent within the 
vitreous as a potential means to overcome these limitations. Three dimensional (3D) MRI 
has shown significant differences between the concentration of gadolinium diethylene 
triaminopentacetic acid (Gd-DTPA) within the vitreous when released from an episcleral
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implant in vivo as compared to diffusion in the ex vivo eye.19 Empirical data were then 
used to calibrate a finite element mathematical model of the rabbit eye for simulation of 
concentration profiles. The study was limited however in that the temporal sampling 
resolution required 26 minutes of imaging time to acquire a single time point and spatial 
resolution was limited by a slice thickness of 1.0 mm.
Recent advances in micro-computed tomography (micro-CT) provide unique advantages 
in pharmacokinetic studies of the eye including excellent temporal and spatial 
resolution. These systems have been shown to be particularly useful in providing real 
time data on drug delivery and distribution in a non-invasive manner. This combination 
of parameters makes micro-CT in particular a more favorable option to study ocular 
molecular transport over other imaging modalities that require a compromise between
' j ' l
scan time, sensitivity and resolution.
The purpose of the work presented here was to create a method of measuring the 
concentration and transport behavior of surrogate ocular drugs following intravitreal 
injections. This has been accomplished by using ex vivo porcine eyes to study the 
movement of a contrast agent within the vitreous. Porcine eyes were chosen for ex vivo 
work because of their similarity in size and structure to the human eye24'27 and the ease of 
access to large numbers of fresh enucleated eyes. Using the acquired data sets, diffusion 
modeling was completed to achieve an improved understanding of the factors influencing 
drug flow through the vitreous.
3.2 Materials and Methods
3.2.1 Micro-CT system
Scanning was performed using a pre-clinical micro-CT imaging system (eXplore Locus 
Ultra, General Electric Healthcare Bioscience, London, Ontario, Canada). The system 
possesses the capability of combining the high resolution of micro-CT with the fast 
scanning speed of clinical CT. A flat-panel detector mounted on a slip-ring CT gantry 
was used to acquire images with an isotropic spatial resolution of 150 pm. Each 3D
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volume was acquired in 8-16 seconds and provided a reconstructed 15 cm field of view 
with axial extent of 15 cm. X-ray acquisition parameters (80 kVp and 40-80 mA) were 
kept constant for each experiment.
3.2.2 Injections and Scanning
Enucleated porcine eyes were obtained from a local abattoir and used within 10 hours 
postmortem. During scanning and for the remainder of the study, they were maintained at 
24°C (+/- 2°C). An enclosed plastic case was used for simultaneous scanning of multiple 
eyes while ensuring the eyes were stabilized, using 50 ml Falcon™ tube covers, and 
hydrated, using PBS soaked medical gauze (Figure 3.1).
A baseline volume was obtained prior to injection of contrast agent to screen for 
anatomical irregularity of the eyes. Intravitreal injections of diluted iohexol, a low- 
osmolar non-ionic iodinated contrast agent (Omnipaque 300, GE Healthcare, Oakville, 
Ontario, Canada) and gold nanoparticle contrast agent (AuroVist™, Nanoprobes Inc, 
Yaphank, New York, USA), were used as drug surrogates and tracer sources. To provide 
quantitative measurements and analysis using the CT number in Hounsfield units (HU) 
output by the system, standard solutions of known contrast agent concentrations were 
scanned with the eyes for calibration purposes.
The intravitreal injection technique was taught by ophthalmologists and medical 
residents, with a focus on mimicking a clinical injection to humans. All intravitreal 
injections were performed manually using 0.3 ml syringes attached to 29 gauge needles 
(SS05M2913, Terumo Medical Corporation, Somerset, NJ, USA). Each eye received a 
single 30 pi injection of a specified concentration. The needle was gently advanced 
through the sclera approximately 2-3 mm posterior to the superotemporal limbus and 
inserted to the appropriate depth of 1 cm (marked on the needle) to achieve a clinically 
relevant mid-vitreous injection in the porcine eye. Contrast agent was injected and the 
needle carefully withdrawn to minimize reflux along the in situ track. Immediately after 
injections were completed, the case was carefully positioned in the micro-CT scanner.
37
Experiments were performed with multiple eyes in the plastic case. Each eye received a 
single injection of a specified concentration. Varying concentrations were used to 
determine the effect of different dilutions in the transport of the drug surrogate for the 
duration of the experiment. In the first experiment, a volume of 30 pi of iodine solution 
was used in the following concentrations: 150, 75, and 37.5 mg/ml (n = 12). For the pilot 
experiment, CT images were acquired at 12, 22, 32, 52 and 72 minutes (time 0 is at 
injection of the first eye). 3D scans at varying time points allowed for the measurement of 
the injected bolus’ movement in all directions. Based on the results identified in this pilot 
experiment, all subsequent injections in the second experiment (n = 18) were carried out 
with a volume of 30 pi and at iodine concentrations of 150, 37.5, 18.75, 9.38, and 4.59 
mg/ml. Images were acquired at 8, 12, 24, 36, 48, 96, 144 and 192 minutes post-injection. 
Gold nanoparticle solutions were administered in porcine eyes (n=6) at concentrations of 
100, 25 and 6 mg/ml. Images were acquired at 3, 5, 6, 8, 9, 11, 19, 35, 67, 131, 195, 230 
minutes post-injection.
Figure 3.1 Enclosed container for ex vivo eyes in micro-CT scanner
An enclosed box was used to stabilize and the eyes in a closed environment for the full 
duration of the experiment following intravitreal injections of contrast agent. A) The box 
was designed to allow for multiple eyes to be scanned simultaneously and B) fit within 
the scanner’s bore and field of view.
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3.2.3 Image Analysis
CT data were analyzed with dedicated 3D visualization and analysis software 
(MicroView 2.1.2, General Electric Healthcare, London ON), which allowed the 
specimens to be viewed as multi-planar reformats or as cross-sections through the axial, 
sagittal and coronal planes (see Appendix A). After attainment of calibration curves to 
correlate CT density to contrast concentration, HU attenuation of intra-ocular voxels was 
converted to concentration units for further analysis.
Custom 3D regions of interest (ROIs) describing the spatial and temporal distribution of 
contrast agent were automatically calculated based on CT numbers (HU) using 
MicroView (see Appendix B). These regions were superimposed onto the image with 
subsequent ROIs to show varying concentrations at a single time point. Alternatively, 
ROIs for varying time points, but for a single concentration, were used to qualitatively 
show the movement of an iso-concentration over time. Lastly, both of these scenarios 
provide a means of measuring (ImageJ 1.41, NIH, Maryland, USA) the injected bolus’ 
changing concentration and movement over time.
The center of the injected bolus was assumed to be the point that had the highest CT 
number. This was found by creating a ROI around the bolus and generating a histogram 
from MicroView that plots number of pixels versus CT number (HU). The location of the 
greatest intensity was then used as the assumed center of the bolus. A line was placed in 
the horizontal direction (coronal and sagittal) centered about the maximum value. A line 
profile plot was created with CT number (HU) against distance. For the remaining time 
points, the line profiles were placed in the exact same position of the scan to eliminate 
errors caused by any potential movement of the bolus center (see Appendix C for further 
information). These observed data were used to calculate the concentration profile of best 
fit in the diffusion model.
3.2.4 Calculation of Diffusion Coefficients
A model for diffusion from an instantaneous spherical source was chosen from Crank 
(1975) for the analysis of the intravitreal injection data. This model assumes that the
diffusing substance is moving uniformly through an isotropic infinite medium (r = 0 at t 
= 0). The concentration Cr at radial position r at time t is given by
f„ r a ~ r  s a + r
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where Co is the initial concentration throughout a spherical bolus with an initial radius a. 
The analyses were based on the assumption that the injected bolus initially creates a 
uniformly distributed 30 pi sphere in the vitreous.
Calculation of the diffusion coefficient (D) for each time point in both the sagittal and 
coronal directions was made by fitting the experimental data with Equation 3.1. Analysis 
was completed in MATLAB (R2009b, The Mathworks Inc., Natick, MA) where custom 
code was used for background removal, data range selection, non-linear curve-fitting 
using least squares method and regression analysis (Appendix D). This approach was 
used to optimize the coefficient of determination (R ) of the curve fits and provide the 
confidence intervals (Cl) at a significance level of 95%. Diffusion coefficient values were 
selected for if an R2 > 0.90 was achieved.
3.2.5 Reflective and Absorptive Boundaries
The behavior of the drug surrogate diffusion at a boundary, such as at the retina, was 
studied using previously derived models. Mitra et al. (1993) presented the following 
perturbation expansion of the non-Gaussian time dependent diffusion coefficient D(t) for 
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where Do is the diffusion constant of the bulk fluid, S/Vp is the ratio of surface area to 
pore volume, t is time and a is the radius.
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3.3 Results
Reconstructed 3D images allowed for the visualization of contrast agent in the vitreous 
following a mid-vitreal injection into ex vivo porcine eyes (Figure 3.2). Major features of 
the porcine eye were also visible such as the cornea, lens and sclera. This allowed for 
measurements of vitreous and lens dimensions to improve accuracy of future injections. 
Injection concentrations of at least 6 mg/ml were sufficient to allow for visualization of 
the injection in the vitreous, from the background, over an extended period of time. The 
relationship between CT number (HU) and iodine concentration was calculated and 
showed a very strong linear correlation (Figure 2.2), as expected. It was established that 
measurable quantities of contrast agent began to reach the back of the eye (retinal 




Figure 3.2 Micro-CT image of ex vivo porcine eye
Reconstructed 3D micro-CT image of an ex vivo porcine eye with intravitreal injected 
iodinated contrast agent (Omnipaque™) 12 minutes post-injection. Visible anatomical 
features are labeled (cornea, lens, sclera).
The 3D surfaces of the injected bolus (ROIs) (see Appendix B), that were created to 
represent the bolus, provided visualization of contrast concentrations at each time point. 
For each eye specimen, several ROIs were superimposed to qualitatively show varying 
concentrations at a single time point (Figure 3.3a). This provided an excellent means of
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viewing how the concentration of contrast was distributed within the bolus and the effects 
of time. Alternatively, ROIs for varying time points and for a single concentration were 
used to qualitatively show the movement of a single concentration over time (Figure 
3.3b). Both of these scenarios provided a means of viewing the injected bolus’ changing 
concentration and movement over time.
Figure 3.3 Isoshells representing concentrations in sagittal slice of micro-CT scan
A) 2D sagittal micro-CT image of ex vivo porcine eye following 30 jnl intravitreal 
injection of iodinated contrast agent (Omnipaque™) with 3D regions of interest 
representing specific concentrations from 6 to 105 mg/ml at 12 minutes post-injection.
B) 2D sagittal micro-CT image of ex vivo porcine eye following 30 pi intravitreal 
injection of iodinated contrast agent (Omnipaque™) with 3D regions of interest 
representing concentration shells of 10 mg/ml over a time period of 12-72 minutes.
Direct comparisons of the observed data and the predicted (Equation 3.1) have been made 
for each specimen at all time points in which it was scanned. Figure 3.4 shows a typical 
signal profile for the experimental and predicted data after 32 minutes, with the 95% Cl 
around the fit. The R for this case was 0.991 and the confidence intervals are 91.503 HU, 
which represents less than 0.6% of the maximum CT number (HU). In general, the 
experimental data followed a Gaussian distribution curve and the time evolution of the 
mass density functions is consistent with a diffusive transport process.
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Distance from center of bolus (mm)
Figure 3.4 Observed and predicted signal profile through bolus
2D signal profile at 32 minute time point displaying observed profile from micro-CT 
image line profile (solid line) that was obtained through the center of the injected bolus 
and predicted profile from passive diffusion equation (dotted line) with 95% confidence 
interval limits shown (dashed lines).
Diffusion coefficients were found from the optimal curve fits of the signal profiles. The 
combined results for iodinated contrast agent tests are shown in Figure 3.5 for the 150 
and 37.5 mg/ml initial iodine concentration, where the diffusion coefficients for the 
horizontal (Figure 3.5a) and vertical directions (Figure 3.5b) are plotted against time. The 
diffusion coefficients have a mean of 4.76><10"4 mm2/sec and standard deviation of 
7.79xl0'5 mm2/s for 150 mg/ml iodine concentration and 6.10xl0~4 ± 1.61x10“4 mm2/s 
for 37.5 mg/ml concentration. The R2 values have a mean of 0.940 and a mean Cl of +/- 
1.69% of the maximum CT number. The diffusion coefficient values lie slightly above 
the Wilke-Chang estimation (2.8x1 O'4 mm2/s). It should also be noted that they appear to 
reduce with time and there are fewer values that meet the R2 > 0.90 criteria at later time 
points.
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Figure 3.5 Iodine solution diffusion coefficients
Plot of calculated diffusion coefficients in the A) horizontal direction and B) vertical 
direction of iodine at 150 (closed circle) and 37.5 mg/ml (open triangle) concentration in 
vitreous against time in which micro-CT scans were acquired. Values are compared 




Figure 3.6 Gold nanoparticle diffusion coefficients
Plot of calculated diffusion coefficients in the A) horizontal direction and B) vertical 
direction of gold nanoparticles at 10 (closed circle) and 2.5 mg/ml (open triangle) 
concentration in vitreous against time in which micro-CT scans were acquired. Values 
are compared against the Stokes-Einstein estimation (dashed line).
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Diffusivity values of gold nanoparticles in the vitreous are shown in Figure 3.6 for 10 and 
2.5 mg/ml concentrations in the horizontal (Figure 3.6a) and vertical (Figure 3.6b) 
directions. The diffusion coefficients for the gold nanoparticles have a mean of 6.72x1 O'4 
mm2/sec and standard deviation of 3.20X10“4 mm2/s for the 10 mg/ml concentration and 
9.07x1 O'4 ± 7.60x1 O'4 mm2/s for the 2.5 mg/ml concentration. The R2 values have a mean 
of 0.940 and a mean Cl of +/- 3.30% of the maximum CT number. Diffusion coefficients 
for gold nanoparticles appear to approach the Stokes-Einstein estimation (1.44x1 O'4 
mm /s) with time.
The average normalized diffusion coefficients for iodine and gold nanoparticles solution 
in the vitreous are plotted against length characteristic diffusion 1/2(D0f f 12 in Figure 3.7 
and have been compared using the reflective (Equation 3.2) and absorptive (Equation 3.3) 
boundaries analysis. It has been assumed that bulk diffusion Do = 6x1 (f4 mm2/s and the 
bolus center is 4-7 mm from the retina. This model suggests that the retinal zone is acting 
like a reflecting boundary and affecting the estimated diffusion coefficient.
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Figure 3.7 Reflective and absorbing diffusion
Average normalized diffusion coefficients plotted against length characteristic diffusion 
for experimental values of A) iodine (150 mg/ml) and B) gold nanoparticles (10 mg/ml) 
in the vitreous in the horizontal direction, sagittal (closed circles) and coronal (open 
circles), compared against numerical simulations of reflective (solid curve) and absorbing 
(dashed curve) for a spherical pore.
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3.4 Discussion
The framework developed in this study has enabled real-time tracking of a contrast agent 
bolus, delivered as a drug mimic via intravitreal injection, through the vitreous to the 
desired retinal fate. The framework permits not only visualization of the bolus in the 
same specimen over an extended period of time, but also quantitative evaluation of the 
bolus evolution.
3.4.1 Capabilities of Micro-CT in Ocular Drug Transport Study
Recent studies attempted determination of the distribution of drug surrogates in the eye 
following intravitreal injection in vivo, but failed to provide coupled spatial and temporal 
information.30 The necessary spatial resolution was achieved in the work presented by 
using a pre-clinical micro-CT scanner, rather than MRI. ’ With CT, it was possible to 
estimate concentrations of contrast agents to within +/- 0.027 mg/ml over a range of 6 to 
300 mg/ml for iodine and 3 to 150 mg/ml for gold nanoparticles with a spatial resolution 
of 150 pm. The pre-clinical micro-CT scanner also provides the necessary fast scanning 
speed to achieve the temporal resolution required to model transport and flow within the 
eye. The same specimen can be monitored almost continuously with scans acquired every 
90 seconds over a number of hours. This approach allowed for the visualization of drug 
surrogate concentration (Figure 3.3a) and movement (Figure 3.3b). Both of these 
scenarios provided a means of viewing the injected bolus’ changing concentration and 
movement over time. This is compared to the discontinuous data set achieved by 
sacrificing many specimens at different time points, such as in snap freezing, which 
lacks consistency and reproducibility. Through the use of overlay in post-imaging 
processing, such as Figure 3.3, it was found there is preferential flow in the vertical 
direction and the drug surrogate closely followed the shape of the lens when the injection 
site was near the lens. This study provides the proof-of-concept data that micro-CT 
systems available today provide the high resolution, short scan times and near continuous 
scan time points to accurately track contrast in the vitreous from delivery to target tissue 
fate.
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3.4.2 Modeling Ocular Drug Transport Using Experimental Data
The real-time empirical data acquired from the micro-CT scans of the injected intravitreal 
bolus have enabled comparison with a ‘benchmark’ bulk diffusion model to aid the 
interpretation of the results. Diffusion is thought to be the predominant transport 
mechanism for ocular drugs through the vitreous humor and we have been able to 
determine the apparent diffusion coefficients of iodine and gold nanoparticle solutions in 
the vitreous of the eye. Micro-CT allows for simple measuring of the signal profiles in 
any direction with a high resolution and sensitivity. These profiles can be used to fit a 
mathematical model (Figure 3.4) and provide a means of calculating to what degree 
diffusion is responsible in drug surrogate flow.
Average diffusion coefficients calculated for the iodine and gold nanoparticles did not 
correlate with the expectation that they would be inversely proportional to the molecular 
weight. The diffusion coefficient in the vitreous, when compared to an aqueous solution, 
has been shown differ from the assumption of being inversely proportional to the 
molecular weight.31 Both iodine and gold nanoparticles demonstrated time dependent 
effects and at later time points approached the diffusion coefficients from Wilke-Chang 
and Stokes-Einstein estimations, respectively. Density drive gravity flow in the vertical 
direction could also be a contributing factor with higher concentration solutions. The 
asymmetry and translation of the signal profiles (see Appendix C) and the reduction in 
the magnitude of the apparent diffusion coefficients with time (as the overall bolus 
concentration and specific gravity reduces with diffusion) support this hypothesis.
It can also be suggested that diffusion within a finite volume is affecting the behavior. 
Diffusion coefficients that reduce with time could be a result of the drug surrogate 
reaching a reflecting boundary, the retina. A number of researchers have investigated 
diffusive phenomena in finite volumes, adjacent to absorptive and reflective 
boundaries.32'34 The comparisons in Figure 3.7 show a reasonable match, thus this 
appears to be a plausible hypothesis and is further supported by reductions in the R 
values for the fits with the Gaussian model (Equation 3.1) at later time points.
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3.4.3 Limitations
A limitation of the current study is the use of contrast agents as drug mimics for ocular 
drugs. Omnipaque was chosen as the contrast agent in these experiments due to its 
common use with micro-CT applications and well-defined properties, reliability and cost 
effectiveness. Gold nanoparticles have a closer molecular weight to common intravitreal 
drugs and has been shown to be a suitable source of contrast and a tracer to allow proof- 
of-principle tests to be realized. Modifying ocular drugs (bevacizumab or ranibizumab) 
for detection in future micro-CT scanning is essential to provide clinically relevant 
information on drug transport mechanisms. In particular, stability, density, molecular 
weight and ionic charge of compounds can have significant effects on the observed 
behavior. A competing set of criteria for using the micro-CT technique requires 
radiopaque drug surrogates at suitable concentrations for visualization, but these must 
also be balanced by clinically relevant volumes and concentrations.
The likely significance for in vivo studies has yet to be determined, since both diffusive 
and advective flow will be occurring. ’ This ex vivo study elucidates diffusion effects 
and can be deconvolved from future in vivo work to correctly understand the role of 
advection. Further work will also involve the development of more sophisticated 
computational fluid dynamics approaches to provide further understanding of the time 
dependent coupled diffusion and advection transport behavior in a finite volume.
3.5 Conclusions
Mid-vitreous injection of iodinated and gold nanoparticle contrast agents as a drug mimic 
using ex vivo porcine eyes and micro-CT scanning provides an accurate high resolution, 
non-invasive method of spatial and temporal tracking of the bolus and concentrations. 
The ability to extrapolate pharmacokinetic profiles from any region of the vitreous at 
various time points provides extensive information in understanding ocular drug flow. 
Our data show the effects of diffusion and boundary reflection on the movement of the 
solutions in the vitreous body. Knowledge that a drug compound is reaching the retina at 
a specific concentration and at a particular time after injection is vital information that
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has not been visualized to date. The results shown have provided the required ex vivo 
proxy to apply the framework to in vivo experiments in rabbits. This work has provided 
the initial steps towards a better understanding of the mechanisms of drug transport when 
administered through the vitreous using micro-CT scanning.
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Chapter 4
4 Identification of anomalous features of intravitreal 
injections using micro-computed tomography
This chapter describes the identified anomalous features that impact drug delivery in the 
eye as a result o f  an intravitreal injection. Three-dimensional micro-computed 
tomography images were used to detect characteristics not normally identified or studied 
following an intravitreal injection. The presence o f  air bubbles and inconsistent bolus 
shapes have indicated that intravitreal injections have high variability. It is only through 
the realization o f  these anomalous features that the efficacy o f  intravitreal drug delivery 
will be improved through a consistent and accurate injection technique.
4.1 Introduction
Intravitreal injections remain a common technique for administering ocular drugs to the 
posterior segment of the eye, especially for treatment of age-related macular 
degeneration. Aspects of intravitreal injections, such as drug reflux, leakage from the 
needle tract and needle depth, are known to be of importance for the efficacy of 
intravitreal drug delivery. 1 Although, several types of symptomatic complications have 
been shown to occur as a result of these injections.2' 4 With improved efficacy through 
injection technique, it is expected there would be a reduction in the number of 
complications associated with intravitreal injections.
Some complications that are less studied are the introduction of air or silicone into the 
eye. Air bubbles have been previously documented and are seen clinically following 
intravitreal injections, 5 but there has been little reporting on the size and fate of these air 
bubbles. Other clinical reports have found intravitreal silicone oil droplets present within 
the eye following intravitreal drug injections. ’ These are believed to have originated
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• 8from the needle as a result of the manufacturing or repackaging processes. Any factors 
that may affect the therapeutic efficacy of the drug being administered by intravitreal 
injection, such as the introduction of bubbles in the vitreous, should be addressed.
Pharmacokinetics in the vitreous is influenced by a number of factors. The more well-
known and understood include molecular size of the drug,9’10 vitreous liquefaction, 11
vitreous volume, 12 intraocular pressure13 and intraocular inflammation. 14 Some factors,
such as vitreous liquefaction or volume, cannot be changed through treatment options.
The differing properties of the vitreous as a result of vitreous heterogeneity15,16 can
significantly alter how a drug travels through the vitreous in terms of time and route. The
distribution of drug in a liquefied vitreous has been shown to be faster than that of a
normal vitreous17 and the effect on drug kinetics is largely influenced by the location of 
1 8liquefaction.
Many pharmacokinetic modeling studies, and therefore drug dosages, are administered 
based on assumptions of a specific bolus shape19,20 and location of injection,21 but 
deviations from these assumptions and predications change the flow and dosage window 
of the drug. Therefore, the most efficient and effective outcomes for the target tissues 
may not be realized. The purpose of the work presented in this chapter is to identify and 
address anomalous features found following intravitreal injections using a porcine and 
rabbit eye model. With direct spatial and temporal visualization of drug boli from 
intravitreal injections using micro-computed tomography, we are better able to 
understand the impact of anomalous features on drug delivery in the eye.
4.2 Methods
4.2.1 Micro-Computed Tomography
Micro-computed tomography (micro-CT) scanning was performed using a pre-clinical 
system (eXplore Locus Ultra, General Electric Healthcare Bioscience, London, Ontario, 
Canada). A flat-panel detector mounted on a slip-ring CT gantry was used to acquire 
images with an isotropic spatial resolution of 150 pm. Each 3D volume was acquired in
8-16 seconds and x-ray acquisition parameters (80 kVp and 40-80 mA) were kept 
constant for each experiment.
4.2.2 Intravitreal Injections
Freshly harvested enucleated porcine eyes were obtained from a local abattoir and used 
within 10 hours postmortem. During scanning and for the remainder of the study, they 
were maintained at 24°C (+/- 2°C). Pre-injection scans confirmed no abnormalities in any 
eyes. Iodinated (Omnipaque™ 300, GE Healthcare, Oakville, Ontario, Canada) and gold 
nanoparticle (AuroVist™, Nanoprobes Inc, Yaphank, New York, USA) contrast agents 
were used as drug mimics at varying concentrations. Clinically relevant intravitreal 
injections of a 30 pi volume of contrast agent were administered into 24 enucleated eyes. 
Injections were performed 2-3 mm posterior to the superotemporal limbus at a depth of 1 
cm using 29-gauge needles (SS05M2913, Terumo Medical Corporation, Somerset, NJ, 
USA). Each injection lasted for approximately 2 to 4 seconds.
An additional experiment was performed using ex vivo rabbit eyes to investigate the 
effects of flow rate on intravitreal injections. Three groups of varying flow rates were 
used and labeled as fast, intermediate and slow injections. Each set utilized three rabbit 
eyes, one receiving an injection via a syringe pump (Harvard Apparatus PHD 4400 Hpsi, 
Harvard Apparatus, Massachusetts, USA) and two receiving hand injections designed to 
mimic a clinical injection. The syringe pump allows for a very accurate volume and flow 
rate administration and provides the capability to exaggerate flow rates: fast (72 ml/hr), 
intermediate (0.6 ml/hr) and slow injection (0.144 ml/hr).
4.2.3 Imaging
Scans of the porcine eyes were acquired up to 230 minutes (the anticipated time for the 
contrast agent to remain at sufficient concentration and/or reach the retina) following the 
injection to allow for visualization of the contrast agent’s progression through the 
vitreous. Grey scale image intensity variations can be used to differentiate between 
tissues in the eye and introduced fluids and gases. If used as a drug mimic, the temporal 
and spatial changes in contrast agent concentration can also be observed as the fluid 
diffuses through the vitreous.
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Experiments performed to investigate the flow rate of intravitreal injections were scanned 
for up to approximately 20 minutes post-injection. Whole volume scans were acquired as 
rapidly as possible. To allow for time for scanner start-up and data transmission, scans 
could be acquired at a maximum rate of every 2-3 minutes.
4.2.4 Image Analysis
The acquired scans were reconstructed and analyzed using dedicated 3D computed 
tomography visualization and analysis software (MicroView 2.1.2, GE Healthcare, 
London, Ontario, Canada). Upon examination of the reconstructed scans, anomalous 
features of air bubbles and irregular bolus shapes were realized.
To better understand the behavior of the air bubbles over time, measures of diameter 
were taken using signal profiles and 3D regions of interest. The location of each air 
bubbles was also recorded by its center x, y  and z  coordinates. All air bubbles resembled 
perfect spheres and the volume was calculated using the sphere volume equation with the 
measured diameter. Plots of bubble volume (F) with time (/) were produced and 
assuming first order kinetics, the slope of these lines were found, providing the decay 
constant (k), of the following exponential decay equation:
V = V 0-ekt (4.1)
where Vo is the assumed initial volume of the bubble.
Analysis of the initial bolus shapes was completed by measuring the length, height and 
width of a reference rectangular prism into which each bolus fit. It should be noted that 
due to the irregularity of the shapes, these measures only provide an approximation of the 
shape of the boli. Surface area of the initial bolus was calculated by creating a 30 pi 
isosurface around the injected contrast agent. From this the surface area was 




Despite using typical clinical procedures to eliminate air from entering the vitreous 
during hand injection (e.g. vertical positioning of needle, while tapping the syringe and 
pushing out air), air bubbles were clearly visible within the vitreous (Figure 4.1) of 21 
eyes following the injections and totaled 36 air bubbles.
♦ * ***
♦ /  \





Figure 4.1 Air bubbles seen in micro-CT scan
Micro-computed tomography image showing air bubbles outlined as grey isosurfaces 
found within the vitreous following intravitreal injection. Inset image is a 2D slice 
through the injected contrast agent (white region) with the presence of an air bubble 
(black circle).
The initial volume of the air bubbles ranged from 0.01 pi to 1.50 pi in volume and the 
mean was 0.03 pi. Some movement (~ 1 mm in any direction) of the bubbles occurred
59
over the scanning period of 230 minutes. The size of the bubbles was found to decrease 
over this visualization period (Table 4.1).
Table 4.1 Air bubble changes over time in the vitreous
Air bubble characteristics and the changes over the period of 120 minutes post-injection.
Variable 5 minutes post-injection
135 minutes 
post-injection
No. per eye (mean) 1.78 1.38
Volume (pi)
Mean ± SD 0.06 ± 0.09 0.04 ± 0.07
Minimum 0 . 0 1 0 0 .0 0 1
Maximum 1.483 1.421
Using the first order kinetics assumption, the decay constants of these bubbles (£) had a 
mean of 0.0067 ± 0.0022 min'1. Hence the bubbles had half-lives of 0.09 ± 0.02 days, 
which is somewhat shorter than in vivo observations of free non-expansile gaseous 
bubbles have found previously.22 This may be due to the size of the air bubbles; previous 
studies have used large bubbles relative to the eye volume and the relationship between 
surface area and volume is quite different for smaller bubbles. Further investigation of the 
relative differences in half-life between different sized bubbles is shown in Figure 4.2, 
where the decay in bubble volume with time is shown for four typical bubbles with sizes 
ranging from 0.01 to 0.57 pi are shown. Each decay sequence has been fitted with 
Equation 4.1 to find the half-life, which is seen to reduce with bubble size.
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Figure 4.2 Influence of time on air bubble volume
The relationship between air bubble volume (logarithmic scale) and time that was 
observed in the micro-CT images following intravitreal injections. Lines indicate 
calculated decay using Equation 4.1.
4.3.2 Bolus Shape
Many of the injected boli were found to have abnormal initial shapes (Figure 4.3). The 
assumed shape of a sphere was rarely found; rather characteristics such as two conjoining 
spheres or tear drop shapes often resulted. For an assumed sphere, the diameter would be 
approximately 3.86 mm (based on 30 pi volume). However, the extent of the initial boli 
had a larger range and a higher than expected average (Table 4.2). These asymmetric boli 
were attributed to movement of the needle tip during the injection and reflux of the drug 
mimic up the needle path. There was also no true center of the boli (i.e. no single region 
with a peak contrast concentration) when the initial shape was abnormal.
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Figure 4.3 Bolus shapes shown in micro-CT images
Micro-computed tomography images showing the abnormal shapes as a result of needle 
movement during the intravitreal injection with the grey isosurface outlining the injected 
contrast agent in three different specimens.
Table 4.2 Injected bolus dimensions
30 pi bolus shape dimensions in first scan after injection (5 minutes)
Variable Length (mm) Height (mm) Width (mm)
Mean ± SD 4.57 ± 1.01 5.67 ± 1.33 4.73 ±2 .12
Minimum 2.85 3.81 2.98
Maximum 6.39 8.49 4.92
4.3.3 Injection Flow Rate
The slow flow rate injection of 0.144 ml/hr, or for the duration of 12.5 minutes, provided 
visualization of how the injected solution disperses into the vitreous to form an initial 
bolus (Figure 4.4). Rather than forming a sphere at the very tip of the needle, the injected 
solution forms up around the needle and disperses in a pattern to look like it is being 
pushed away from the needle.
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Figure 4.4 Micro-CT images with needle in place during injection
Micro-CT imaging of intravitreal injection and bolus formation in the vitreous with the 
needle in place during a 12 minute duration injection (0.144 ml/hr) using a syringe pump.
The slow and intermediate flow rates did not provide visualization of how the bolus 
formed over time due to the temporal resolution limitations of the scanner. A scan was 
completed in all cases immediately after the injection was completed and the surface area 
of the 30 pi volume difference is shown in Figure 4.5. A 30 pi sphere would have the 
surface area of 46.71 mm and is shown in Figure 4.5 as a means of comparison. There 
does appear to be a trend of a higher surface area for faster injection flow rates. It was 
observed that a higher injection velocity resulted in the drug being ‘pushed’ further into 
the vitreous and therefore resulted in an unexpected initial shape and location. This was 
evident in both the hand injections and syringe pump injection.
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Figure 4.5 Surface area of bolus compared with injection duration
Measured surface area of a 30pl injected bolus of contrast agent following an injection at 
multiple flow rates (durations): 0.144 ml/hr (750 sec), 0.6 ml/hr (180 sec) and 72 ml/hr 
(1.5 sec). A comparison was made with that of an ideal sphere with a volume of 30 pi 
(dashed line).
4.4 Discussion
Although the presence of small air bubbles within the vitreous are not thought to be a 
significant risk for patients, it is desirable to minimize their size, since they may cause 
temporary vision impairment. In addition, the transport of the drugs from the injected boli 
may be hindered due to the increased tortuosity of the diffusion/flow path around the air 
bubbles. It is important to be aware of the factors influencing pharmacokinetics so that 
the standard method of drug administration is as effective as possible in disease 
treatment. Whilst the air bubbles are likely to migrate upwards (due to buoyancy forces), 
a patient’s position during and following the injection, in addition to pressure gradients or 
flow in vivo, are also likely to affect air bubble movement. It was found that of the three 
specimens used for syringe pump injection, none had evidence of air bubbles following 
injection. Possible sources for these air bubbles may be inadequate de-airing of the needle 
barrel system, cavitation or air entrainment during insertion.
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The most obvious source of the air bubbles would be transfer from the needle or the 
barrel of the syringe. Interestingly, the initial volume of the air bubbles was found to be 
quite large compared to the internal volume of the 29 gauge needles used (up to 5 to 6  
times as great). Thus additional air may have been present in the syringe barrel, lying at 
the interface of the rubber piston and the sides of the syringe barrel. However, given the 
care taken during preparation to remove air from the system and that the plunger was not 
pushed completely to the end of the barrel during injections, this source of air is unlikely.
Hydrodynamic cavitation has been observed to cause microscopic air embolisms in other 
forms of injection,23,24 but it is not thought to occur with standard syringes and 
injections. However, it has been observed through micro-orifices and micro-fluidic 
devices for low Reynolds number flows.26 Since the barrel-needle interface is defined as 
a ‘sharp-edged orifice’ in flow terms, the sudden reduction in cross-sectional flow area 
will induce a static pressure drop at the vena contracta (narrowing of flow) that occurs 
just beyond the interface. If this drop is sufficiently large and the pressure begins to 
approach the vapor pressure of the fluid, then cavitation and the growth of micro-bubbles 
could occur in the flow. Whilst this mechanism is less likely for standard (4-5 second) 
injection times, this cannot be discounted at this stage for shorter periods of injection. 
Confirmation of this phenomenon would require further careful study and complex multi­
phase computational fluid dynamics approaches.
Another possible source of air could be entrainment during needle penetration of the 
sclera. A number of examples of physical problems where small objects penetrate liquids 
and films leading to air entrainment are described in the literature. It is therefore 
conceivable that surface tension forces at the air-liquid-needle interface are sufficient to 
pull small volumes of air into the vitreous as the bevel and needle penetrate the sclera. 
Further study of these injections in a sub-aqueous state would confirm this hypothesis.
Some prefilled syringes are available and useful in reducing or eliminating gas bubbles 
from the syringe. The techniques in which the syringes are filled vary greatly and not all 
methods are equally effective in removing air from the syringe barrel. More advanced 
vacuum filling provides bubble-free filling and therefore improves dosing accuracy,
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product stability, improved sterility and no introduction of air during injection. Recent 
work has shown foreign materials, such as silicone oil, may still be introduced during
O
intravitreal injections when using prefilled syringes. If hydrodynamic cavitation is the 
source of air in the injection, prefilled syringes would not have any effect. Not all 
prefilled syringes are manufactured and filled in the same way, but they do provide 
potential for improving the efficacy of drug delivery in the eye.
Based on the observations of the resulting boli shapes after injection, delivery of the drug 
cannot be based on predictions where the initial bolus is assumed to resemble a sphere. 
Further experimental observations seems to indicate that the initial bolus shape is also 
related to the fluid velocity exiting the needle and the stability of the syringe. A higher 
injection velocity resulted in the injected solution to travel further into the vitreous and 
further deviated from an expected sphere bolus. The vitreous is a paucicellular hydrogel 
with primarily unbranched type II collagen fibrils and hyaluronic acid. These fibrils 
form a tensioned semi-random polymer network, where the hyaluronic acid sustains the 
tension by osmotic (Donnan) swelling. Investigations of the elastic shear moduli using 
observations of spherical cavity instability of injected fluids into the vitreous cavity have 
indicated that this tensioned structure is relatively easy to disturb and that the 
déstructuration is strain rate (i.e. fluid velocity) dependent.30 In addition, the fulcrum of 
the needle is the entry point of the sclera, which will effectively magnify any movements 
o f the individual performing the injection. Thus the insertion of the needle, subsequent 
movement, outflow velocity and instabilities in the vitreal collagen network will all lead 
to the observed asymmetry of the boli.
For potential changes to be made to the delivery method of ocular drugs it is important to 
understand and address the factors in drug delivery that can be altered. Drug loss as a 
result of reflux has been shown to be a highly variable factor in ocular drug delivery. It 
has been estimated that 1 0 % loss of drug could be substantial enough to alter the 
pharmacokinetics and therefore effectiveness in treating the disease. 1 Work has been 
completed recently that found the use of 30G needles and a deep injection helps to 
minimize reflux of drug during intravitreal injections. 1 The study showed that with minor 
modifications to injection supplies and technique, significant improvement can be made
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to administering the drug in the expected manner, thereby maximizing the therapeutic 
effect. Our work has broadened and enhanced these observations with direct spatial and 
temporal visualizations of the drug boli and associated phenomena following injection.
This is also the first work to date that has imaged an intravitreal injection while 
maintaining the needle inserted in the eye. Limitations of the work associated with 
injection flow rate is that it was a preliminary study that had only one specimen per group 
with use of the syringe pump. To determine statistical differences further work would be 
required. This experiment provided the necessary understanding of what is required to 
administer an injection using a syringe pump and better understand what effect flow rate 
has on intravitreal injections.
4.5 Conclusions
The observation and study of intraocular air bubbles, inconsistent bolus shapes and flow 
rate variations have demonstrated the importance of a consistent and accurate injection 
technique to administer the appropriate concentration of drug to the retinal tissue. They 
also suggest that the design and length of the needle and the injection fluid velocity must 
be carefully considered while administering intravitreal drugs, as this can alter the 
concentration and period of drug reaching the target site. Pharmacokinetic modeling 
assumptions must closely resemble clinical scenarios to provide the most meaningful 
results and this work has helped to develop a greater understanding of the asymmetrical 
initial bolus. It is only by making these anomalous features known and studying injection 
parameters that they can be better addressed to improve the efficacy of intravitreal drug 
delivery and perhaps influence the design of new drug delivery systems, all of which will 
improve patient outcomes and safety.
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Chapter 5
5 Modeling drug transport in the vitreous using 
computational fluid dynamics
This chapter explains the development o f  a computational flu id  dynamics model fo r  drug 
flow  in the vitreous body. Model geometry and transport properties are based on those 
found in ex vivo experimentation using micro-CT. Validation o f  the model is completed 
by using the ex vivo experimental results presented in earlier chapters. The modeling 
presented is a simplified system o f  ocular drug flow  using diffusion based transport 
analysis.
5.1 Introduction
Developing new drugs and drug delivery systems for the posterior segment of the eye has 
become a great interest of vision research. Computational modeling of drug flow is 
progressively being used in the quest for finding a method that requires fewer injections 
and provides more targeted delivery. CFD modeling allows for a variety of tests to be 
performed without using animal or human models. It provides a method of testing and 
insight into the pharmacokinetics of delivery systems such as controlled release 
implants, controlled release drugs and polymeric delivery systems. Recent studies have 
incorporated MRI imaging with model development, but focused on new drug delivery 
strategies, such as iontophoresis,4’5 rather than intravitreal injection.
Initial models of intravitreal drug delivery were developed using the simple geometry of 
a circle to represent the vitreous with retinal permeability being the only boundary 
condition.6 Several studies were developed upon these results and added fluid models 
beyond diffusion, such as Navier-Stokes7,8 and Darcy’s Law.9 CFD models have been 
developed to study drug distribution in the vitreous following intravitreal injections.
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Based on the results of the injected fluorophores in frozen sections of vitreous, a finite 
element model of the rabbit eye was created to study drug distribution after intravitreal
n
injection of fluorescein-based compounds. Models were developed further by 
incorporating the lens and interaction with the anterior portion of the eye (aqueous 
humour and iris) . 7 Friedrich et al. used their model to determine the importance of 
position and volume of intravitreal injections and found that elimination and distribution 
of drug was significantly affected by the injection location. 10 Further work was 
completed and found drugs travelled much faster in aphakic eyes (i.e. the absence of the 
lens) and retinal permeability is an important parameter to consider in understanding drug 
distribution in the vitreous. 11 All of this work demonstrated the complexity and need for 
better understanding of ocular drug flow following intravitreal injections, but very little 
has been validated by experimental evidence.
A major portion of work related to modeling ocular drug delivery has used the rabbit eye 
as a model. 1,7,12 Rabbit eyes are very common in ophthalmic research for their similarity 
in size and properties to that of the human eye. However, rabbit eyes have a very large 
lens and as a result a much smaller vitreous volume than humans. When studying ocular 
drug flow in the vitreous, using a rabbit model, reduced vitreous volume is important to 
consider. Boundary interaction and distances to travel are also key variables to consider 
when developing a model that has the potential for human applications.
The purpose of this work is to develop a CFD model of a porcine eye using the model 
geometry and diffusivity values from micro-CT imaging. Validation of the model will be 
completed using the micro-CT acquired images of intravitreal injected contrast agents 
into the vitreous. It is anticipated the non-invasive imaging will provide important 
temporal and spatial background information to develop the fluid dynamics model 
resulting in a more complete understanding of ocular drug flow in the vitreous.
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5.2 Methods
Model geometry, meshing and finite element modeling was performed within a 
commercially available software package (COMSOL Multiphysics, COMSOL Inc., 
Burlington MA). A 2-dimensional (2D) model was designed to validate the diffusion 
model and material properties. This 2D model was designed to be expanded to a 3- 
dimensional (3D) model that would maintain all of the same parameters.
5.2.1 Initial Conditions
An intravitreal injection was modeled as a hemi-spherical or tear drop bolus with a 
uniform concentration (Equation 5.1),
Ct=o = 1 0  mol/m3 for intravitreal inj ection (5.1)
The hemi-spherical shape was chosen because it is the initial bolus shape in previous 
works studying ocular drug flow in the vitreous and is a common clinical assumption. 
The hemi-spherical bolus was based on a symmetrical sphere of 30 pi volume, resulting 
in a 3.86 mm diameter. The tear drop shape was designed based on the experimental 
results found in the micro-CT study which demonstrated the initial bolus resembles a tear 
drop shape more often than a sphere. The dimensions of the tear drop bolus were 0.74 
mm at the top, where the needle tip would be located, and 3.48 mm at its widest point 
near the bottom. The initial concentration everywhere else in the simulation was set to 
zero (Equation 5.2),
Ct=o = 0 everywhere outside the drug source (5.2)
5.2.2 Governing Equations
A purely diffusive model was designed to replicate the transport mechanisms occurring in 
the ex vivo experiment. To expand upon this model a convective component was added to 
represent what may be found for an in vivo animal model. To determine the convection 
transport of the drug, the Navier-Stokes equation (Equation 5.3) was used to solve the 
flow components of the vitreous humor. Navier-Stokes equations solve for the fluid 
motion using pressure, density and viscosity as parameters. The velocity results were then
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coupled with the convection-diffusion transport equation to determine the distribution of 
drug concentration (Equation 5.4).
p U V U  = -V P  + rjV2U (5.3)
—  + U V C  = D V 2C 
dt
(5.4)
where p  is the mass density, U  is the velocity vector, P is the pressure, 77 is the viscosity, 
t is time, D is the diffusion coefficient and C is the concentration of the drug. It was 
assumed there was no drug reaction, degradation or retardation (due to surface effects), 
so these were not included in Equation 5.4.
5.2.3 Model Geometry
The geometry of the porcine model was based on a simplification of the micro-CT 
images acquired in the study. The thickness of the retina could not be calculated from the 
micro-CT imaging, therefore it was taken from literature. 13,14 Table 5.1 provides details 
o f the dimensions used in the formation of the porcine model and Figure 5.1 shows the 
final geometry used.
Table 5.1 Dimension for model eye
Geometric dimensions of the porcine eye used in the computational fluid dynamics 
model.
Tissue Parameter Value (mm)














Figure 5.1 Domain of vitreous transport model
Porcine eye model geometry and finite element mesh with labeled anatomical features 
that were included in the model and the injected bolus shape/position. Dots (•)  indicate 
points where measures were taken to represent concentration levels at the macula and 
bottom of the eye.
5.2.4 Boundary Conditions and Material Properties
Continuity was assumed for convection-diffusion in all regions except those impermeable 
to the drug. For the surfaces assumed to be impermeable to the drug, lens and sclera, a 
zero species gradient was used,
ÔC
—  = 0 at lens and sclera (5.5)
dn
The hyaloid membrane and a small region of the anterior chamber were included to 
determine the concentration of drug that entered the anterior segment of the eye. 
Anatomically the hyaloid membrane is the boundary between the vitreous and anterior 
chamber. It is composed of highly porous tissue, therefore no resistance was included in
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the transport properties. Material properties were estimated or obtained from the 
literature. The values are shown in Table 5.2. Diffusion coefficients were obtained 
experimentally and calculated from the micro-CT imaging. Average diffusion 
coefficients obtained in the results of the micro-CT study were used since they provide a 
wider range than estimated values from Wilke-Chang or Stokes-Einstein. The inflow 
source was restricted to the pressure of the anterior chamber acting as a normal 
component. The vitreous outflow rate across the retina was calculated based on the area 
of the retina of a typical porcine eye used in the ex vivo work and an outflow rate from 
literature.
Table 5.2 Model parameters for CFD model
Material properties and model parameters used in the pharmacokinetic model.
Constant Value Reference
Diffusion coefficient of iodine 4.76x1 O'6 cm2/s Calculated in this study
Diffusion coefficient of gold 
nanoparticles 9.07x1 O'6 cm2/s
Calculated in this 
study
Density of vitreous 1 g/cm3 Kaufman et a/.15
Density of iodine 1.406 g/cm3 Nath et a/.16
Density of gold nanoparticles 1 g/cm3 Estimated
Dynamic viscosity of vitreous 0.00629 Pa-s Stocchino et a/.17
Dynamic viscosity of iodine 0.002 Pa-s GE Healthcare18
Dynamic viscosity of gold nanoparticles 0.000911 Pa-s Nanoprobes19
Intraocular pressure 2000 Pa Stay et at.2
Vitreous outflow through retina 4.67x10-3 cm/hr Araie and Maurice6
5.2.5 Solution Method
The model geometry was automatically meshed using the built-in software function to 
create triangular elements throughout the domains. Finite element method was used to 
solve the model, where discrete elements are solved using differential equations. To solve 
the computational model, Equation 5.3 was first solved to determine the velocity
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distribution in the vitreous using Navier-Stokes equation. The solution was assumed to be 
time-independent and therefore unaffected by the action of the diffusing drug mimic. The 
resulting velocity field was exported and used in the time-dependent diffusion-convection 
equation (Equation 5.4) to solve for the concentration distribution of the drug mimic in 
the vitreous. All simulations were run on a 2 GHz Core 2 Duo CPU running Windows.
5.3 Results
5.3.1 Validation of Model with Experimental Results
The maximum drug concentration is assumed to be at the center of the bolus. Time 
dependent measurements were taken from both experimental and modeling cases and are 
shown in Figure 5.2. For the purpose of this validation, the initial concentration of the 
bolus in the simulation was set to 150 mg/ml to correlate with the iodine solution 
concentration used in the ex vivo experiment. A strong correlation was found between the 
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Figure 5.2 Concentration at the center of the injected bolus
Numerical model validation with ex vivo experiment data of concentration values at 
center of bolus up to 2 0 0  minutes post-injection, using measured values from 
experimental contrast agent in micro-CT imaging (dots) and CFD modeling (dashed line).
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5.3.2 Effect of Diffusion Coefficients
Diffusion coefficients used in the model were chosen as the two extremes for the contrast 
agents under study. In Figure 5.3, the model predicted concentration profiles are shown 
for the time point of 3 hours, the end point of experimental work completed using micro- 
CT. The profiles indicate due to the small differences in the diffusion coefficient, the 
maximum concentration of iodine within the eye remains at 1.7 times greater than for 
gold nanoparticles. The area of greatest importance is the back of the eye, or the macula. 
Figure 5.4 provides greater information into concentration at specific points by depicting 
the model-predicted concentration gradients for (A) iodine solutions and (B) gold 
nanoparticles at specific points in the eye of the macula and bottom retina. Iodine had the 
lower diffusion coefficient and resulted in longer period for the model to reach uniform 
concentration throughout the entire vitreous. The model was run for a simulation of 24 
hours and iodine had still not reached uniform concentration within the model eye. Gold 
nanoparticles had a higher diffusion coefficient and reached uniform concentration more 
rapidly after approximately 15 hours. However, the iodine remained at a slightly higher 
















































Figure 5.3 Concentration profiles from CFD model
Model predicted concentration profiles for A) iodine solution (4.76 x 10'4 mm2/s) and B) 
gold nanoparticles (9.07 x 10"4 mm2/s) at 3 hours post-injection. Units for the 




Figure 5.4 Concentration gradient at boundary points for contrast agents
Differing diffusion coefficients were used in the model between A) iodine solution (4.76 
x 10‘4 mm2/s) and B) gold nanoparticles (9.07 x 10‘4 mm2/s). Boundary points are located 
at the macula (back of the eye) and bottom of the retina/eye.
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5.3.3 Air Bubbles and Bolus Shape
To determine the extent to which air bubbles and asymmetrical initial bolus shape were 
responsible for ocular drug flow, CFD modeling was completed for each of the scenarios. 
For air bubble analysis, the model was adapted by adding two air bubbles, one of average 
size and the other of maximum size recorded from the ex vivo porcine experiments. The 
one of average size was positioned at the top of the bolus and the larger one at the 
bottom. For bolus shape the model was adapted by using a tear drop shaped initial bolus 
rather than a hemispherical. Figure 5.5 provides the concentration gradients found at the 
macula as a result of these simulations. A direct comparison can be made with the graphs 
found in Figure 5.4B to understand what changes occurred with the presence of air 
bubbles or an asymmetrical initial bolus. The air bubbles resulted in no significant 
change, however the tear drop bolus shape resulted in a higher peak concentration at the 
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Figure 5.5 Concentration gradient at the macula for anomalous features
Model simulations were performed with the presence of air bubbles around the initial 
bolus (dotted) and with the initial bolus in the shape of a tear drop (dashed). Diffusion 
coefficients used in the simulation were for gold nanoparticles (9.07 x 10‘4 mm2/s).
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5.3.4 Convection
The results of the convection-diffusion model simulations showed that the distribution of 
the injected solution reached uniform concentration more rapidly with the presence of 
convection, but concentration profiles remained very similar to those shown in Figure 
5.3. Most interestingly, the concentration of the injected drug at the macula remained at a 
higher concentration for a longer period. Understanding the affect an injected drug has on 
the normal convective flow of the eye is also important. The convective flux is shown in 
Figure 5.6 and demonstrates how the distribution of an injected solution, in this case gold 
nanoparticles, is influenced by active flow. A non-uniform flow pattern is also influenced 

























Figure 5.6 Convective flux and velocity fields in CFD model
Convective flux of the vitreous body is shown in the contour plot and velocity field is 
depicted by the arrows with their respective magnitude. Units of the convective flux 
profiles are mol/m2 s.
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5.4 Discussion
A model was developed for simulation of intravitreal drug delivery in the vitreous body. 
This model is unique from previous ones in that it is based on diffusion coefficients that 
were obtained from extensive experimental data and studies anomalous features of 
intravitreal injections. Developing a computational fluid dynamics model is a favourable 
method in studying fluid transport, as parameters can be easily manipulated and 
parametric studies performed. This model has been developed so that it can be used to 
study other drugs and include additional parameters such as boundary permeability, 
metabolism of drug and altered injection sites. A well-developed model can also be used 
to minimize the number of animals used for in vivo experimentation by doing some of 
the analysis using a CFD model rather than animal model. However, it is very important 
to ensure the model has been developed and validated with high quality experimental 
results.
The strong correlation between the CFD model and the ex vivo data as shown in Figure 
5.2 is an indication that the model developed is representative of what is occurring 
experimentally in porcine eyes when injected with contrast agent. A primary objective of 
this work was to develop a simulation from a computational model that strongly 
resembled the results found experimentally. Correlation of maximum concentration 
values in part demonstrates the correct domain parameters have been set, such as 
diffusion coefficient, density and viscosity. The model solutions also demonstrated strong 
convergence with reciprocal of step size values ranging from 10'3 and 10‘4.
Detailed concentration contour profiles were obtained from the CFD model as shown in 
Figure 5.3. These images provide the spatial information of how a drug is distributed 
throughout the vitreous. Figure 5.4 provides specific point information within the 
vitreous and comparison of the concentration at the target site, the macula, and a 
peripheral region at the bottom of the eye. From these profiles we can see that the drug 
reaches the macula quite quickly and peaks at approximately 5 hours. However, it is 7% 
of the concentration that was initially injected. That carries huge implications for drug 
delivery and the potential to overdose healthy areas of the eye in order to reach sufficient 
levels at the target site.
83
Modeling based on the presence of air bubbles and altered bolus shapes revealed minor 
deviations from the concentration gradients that did not have these features. Air bubbles 
resulted in slightly higher peak values of drug concentration at the macula with 0.3% 
more of the initial concentration than the normal. The teardrop bolus shape had more of 
an effect and resulted in 1.1% more of the initial concentration at the macula than in the 
case of a hemispherical bolus. The full extent of the asymmetrical bolus may not be 
realized because the model is constrained to 2D and could result in larger differences in a 
3D model.
Convection has been shown to be an important parameter to include in ocular drug 
delivery studies, particularly for humans models.2 When a convective component was 
implemented in this study’s model, the concentration profiles did not have much of an 
effect when coupled with diffusion. This could be attributed to the fact that the molecular 
weight of the drug mimic used in this study were much higher than those used in other 
studies that cited convection as a significant transport mechanism. ’ However, by 
creating this diffusion based model an important step has been made in learning more 
about ocular drug delivery. It has been shown by Missel et al. that it is vital to separate 
experiments to deduce diffusion from other transport mechanisms due to the nonlinear
9 ftway that they interact.
A limitation of this model is that it lacks the 3D information that was provided in micro- 
CT imaging. However, the 2D model is simpler to design and implement in terms of 
requiring less computational power and time. There are some limitations to the 
quantitative data provided since homogenous properties of the vitreous and no lateral 
diffusion/dispersion must be assumed. The third dimension that is missing from this 
model would be side-to-side if you were looking into the eye from the front or back. This 
direction is expected to have the same transport properties as the other horizontal 
direction from front to back while boundary interaction would only be an issue at later 
time points. The effect of gravity, particularly for high molecular weight drugs, could 
also be introduced as a potential transport mechanism in the vertical direction as some 
characteristics of it were displayed in micro-CT imaging.
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5.4.1 Translation to Human Model
CFD modeling allows for developed models to be easily translated to other applications 
or systems. It allows for an intermediary step to be established between animal models 
and human testing, by developing a CFD human model. Model geometry can be altered 
to replicate that of the human eye and known material properties and boundary conditions 
revised. The realized properties such as diffusion coefficient and density driven flow 
would be maintained and applied to the human model. The results of such a simulation 
would more closely resemble what may actually occur in a human eye. While the results 
would be based on some assumptions, the efficiency and lack of requirements for human 
subjects makes the research particularly appealing for drug delivery studies.
5.5 Conclusions
A computational fluid dynamics model has been developed based on parameters obtained 
from experimental data. Results from the model correlated extremely well with those 
found in the experimental results performed using porcine eyes. The model is able to 
study the quantitative effects of diffusion or convection and the introduction of 
anomalous features on drug concentration within the vitreous following an injection. The 
model is an excellent resource to create a correlation between ex vivo and computational 
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6 General Discussion and Conclusions
This chapter will provide a brief summary o f  how each previously presented objective 
was addressed in the research. Limitations o f  ex vivo experimentation and the use o f  drug 
mimics will be discussed and means o f  addressing each will be suggested. Potential 
directions that this work can be carried out in the future are explored and the overall 
significance o f  the work completed is highlighted with potential clinical and research 
contributions.
6.1 Summary
The ability to provide a greater understanding of drug distribution and fate of ocular drug 
administration is vital information that can have major clinical implications. Intravitreal 
injections are commonly used to administer drugs to the posterior segment of the eye, but 
little is known as to how the drug flows through the vitreous once it has been injected. 
Use of intravitreal injections for the treatment of AMD and other diseases continues to 
increase as new drugs are developed and drug costs decrease or are covered by health 
insurance.1,2 Toxicological impact and concentration levels of intravitreal injections is 
important because the drug administered directly into the eye. Through the integration of 
non-invasive imaging and computational modeling, new knowledge can be obtained to 
aide in developing changes or alternatives to the current method of drug administration.
To visualize the progression of drug flow through the vitreous in micro-CT imaging, two 
contrast agents were compared as possible drug mimics. Iodine solutions have a very low 
molecular weight and have been well studied in biological systems.4,5 Gold nanoparticles 
have a molecular weight that is similar to that of some anti-VEGF drugs used in AMD 
therapy, but is a relatively new contrast agent for x-ray imaging.66 A variety of testing
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was performed on each of the contrast agents including concentration calibration, dilution 
from the vitreous over time and diffusivity, to determine if gold nanoparticles were a 
viable alternative as a drug mimic for intravitreal injections. It was found that gold 
nanoparticles can be used at lower concentrations for an extended period of time to 
maintain sufficient contrast over iodinated solutions and possess a closer molecular 
weight to intravitreal drugs.
Micro-CT imaging of drug mimic flow through the vitreous allows for spatial and 
temporal concentration profiles to be obtained. This important information allowed for 
accurate diffusivity estimates to be made using Crank’s passive diffusion equation and 
CFD. In addition, time dependent differences in diffusion coefficients led to the 
examination of how the drug interacts with the domain boundaries. The use of an animal 
model allows for insight into the mechanisms of ocular drug transport and the use of 
specialized equipment and experimental configurations that would not be possible in 
human subjects. Furthermore, ex vivo testing allows for evaluation and optimization of 
the experimental methods without the use of live animals.
Complications or abnormalities that develop as a result of intravitreal injections are 
important aspects to be considered when studying ocular drug flow. It was shown in the 
ex vivo experiments that typical intravitreal injections are likely to result in anomalous 
features. These can include air bubbles, the initial bolus taking on the form of irregular 
shapes and differing flow rate of the injection, all of which may impact drug delivery. 
This is the first work that has addressed any of these unexpected characteristics, in part 
due to the unique set up of non-invasive imaging. As a result this could help develop 
more accurate pharmacokinetic computational models.
Using the knowledge gained from the ex vivo specimens imaged using micro-CT and 
analyzed for passive diffusion, a porcine eye model was designed for use in CFD 
modeling. Model dimensions were values measured from the micro-CT images and 
assumptions used in previous models, such as bolus shape, were revised to account for 
what was found from the imaging. Diffusion coefficient values that were calculated in 
earlier work were used within the model and resulted in a strong correlation with the
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experimental concentration results. Spatial and temporal dependent drug concentration 
was the outcome of interest. The necessity to separate transport mechanisms was 
successfully accomplished using ex vivo data and allowed for a strong understanding of 
the diffusive nature of ocular drug flow in the vitreous. The developed model provides a 
strong foundation for expansion into a more complex 3D and constitutive CFD models 
of ocular drug flow in the vitreous.
6.2 Limitations
All experimental work presented here utilized ex vivo porcine and rabbit eyes. This is an 
obvious limitation as it does not allow for a full understanding of ocular drug transport 
within the vitreous because of the absence of any active flow. A pilot in vivo experiment 
was performed with an anesthetized rabbit and syringe pump. Significant problems 
occurred with needle positioning and stability in addition to the challenge of the small 
bore size of the micro-CT. These experiments would be possible if a custom designed 
micro-CT bed was designed to hold the rabbit and position the syringe. Preliminary 
drawings have been designed for this set up and may be employed in future work. 
Despite the inability to acquire in vivo data, it is now fully understood what is required in 
future work if an in vivo setup is desirable.
Radiopaque contrast agents were required for the injected solution to be detectable in the 
micro-CT scans for an extended period of time at a measurable concentration. The two 
contrast agents utilized, iodine and gold nanoparticle solutions, were classified as drug 
mimics for this work. They were used because pharmaceutical drugs used in intravitreal 
injections would not be detected in the micro-CT imaging as they do not possess the 
radiopaque properties required to be viewed from the background or vitreous grey scale 
intensity. Therefore, it cannot be assumed that clinical drugs would act in exactly the 
same manner as the contrast agents when flowing through the vitreous. An important 
aspect of this work was understanding the properties of the contrast agents and 
commonly used intravitreal drugs. From this it was inferred that gold nanoparticles would 
act in much the same way as the most common intravitreal drugs.
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6.3 Future Work
Important steps of this work have been completed and have provided a strong foundation 
for further work to be completed. Minimum concentrations levels of the contrast agents 
studied have been established for future work to balance sufficient signal intensity with 
cost. Gold nanoparticles provide a variety of options with the ability to tag drugs and/or 
dyes to the nanoparticles. This would provide the option to study the drug’s presence by 
multiple imaging modalities and provide insight into how the drug interacts with the 
retinal tissue once it reaches the posterior boundary of the eye.
Micro-CT imaging an in vivo rabbit model would provide the additional active flow and 
clearing behaviour absent in the presented experimental data. Diffusion has been shown 
to be a major contributing factor, if not the principal factor, in drug transport in the 
vitreous. With the knowledge gained from the ex vivo data analysis, the method to 
deconvolve diffusive flow is now known and would play an important role in 
understanding the degree to which active and passive flow play a role.
Advanced CFD modeling could be employed by creating a fully developed 3D model of 
the animal model eye, porcine or rabbit. This model could be used to better understand 
the full effect the drug properties have on ocular drug flow. Specifically, to investigate 
the effect of density, viscosity and molecular weight on drug flow and develop 
recommended prescribing information for a drug with a particular set of properties to 
ensure the required concentration reaches the target site for a sufficient amount of time, 
while not reaching levels of toxicity. Development of new administration methods of 
drugs to the vitreous is gaining popularity and this model could be adapted to understand 
where the ideal location for drug administration.
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6.4 Significance
The ability to accurately model drug transport following an intravitreal injection provides 
vital information to better understand the concentration and time frame for the drug to 
reach the target site. By addressing anomalous features not otherwise studied, the work 
provides insight into potential variation that exists between clinically administered 
intravitreal injections and those modeled in pharmacokinetic studies. The approach of 
creating a link between experimental pharmacokinetic data found from non-invasive 
imaging with CFD modeling makes this work unique and novel. The findings permit the 
development of more accurate predictive tools or models to better understand and 
optimize ocular drug delivery. These tools can be used to provide the medical community 
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Appendix A -  Eye Planes/Orientation
To help understand the orientation and use of planes for the eye in this study, Appendix 
A provides a slice and label for each plane. The lens is labeled in each image it is visible 
and the cornea is depicted with an arrow. The axial plane refers to a top down view where 
all sides can be seen. The coronal plane refers to the plane from one side to the other or 
what one would see looking into the eye or from the back. The sagittal plane refers to a 







Figure A .l Planes used for orientation of the eye in analysis of micro-CT images
The arrow indicates the cornea and the lens is labeled.
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Appendix B -  Contrast Agent ROIs
An example of the 3D regions of interest (ROIs) based on concentration levels of the 
contrast agent/drug mimic in the vitreous are shown in Figure A.2. The ROIs are 
representative of grey scale intensities and are from time points of 8, 48 and 192 minutes 
post-injection, from smallest to biggest.
Figure B.l Isosurfaces representing the diffusing bolus over time
The red surface represents 8 minutes post-injection, the blue 48 minutes and the yellow 
192 minutes.
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Appendix C -  Contrast Agent Bolus Signal Profiles
Examples of signal profiles obtained from the micro-CT images are shown below for two
specimens used in calculating the diffusion coefficients.
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Figure C.l Line signal profiles through the bolus
Signal intensity vs. distance taken at each time point in the x (horizontal), y (vertical) and 
45° directions for A) 150 mg/ml iodine in sagittal plane B) 150 mg/ml coronal plane C) 
37 mg/ml in sagittal plane D) 37 mg/ml in coronal plane.
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Appendix D -  MATLAB Implementation Code
Custom made MATLAB optimization code for calculating curve of best fit with diffusion 
coefficient variable.
% C a lc u la te s  t h e  p r e d i c t e d  c o n c e n t r a t i o n  v a lu e s  u s in g  t h e  p a s s i v e  
d i f f u s i o n
% equa t ion  (Crank)  based on t h e  d i s t a n c e  i n p u t .
%
%Where:
%I = i n t e n s i t y  l i n e  p l o t ;  Co = i n i t i a l  c o n c e n t r a t i o n ;  V = 
i n j e c t i o n  vo lum e ;
%D = d i f f u s i o n  c o e f f i c i e n t ;  t  = t im e  s i n c e  i n j e c t i o n  
%
%Created b y  CAS on 0 4 -D e c -0 9 .
c l e a r  a l l  
c l o s e  a l l
% g lo b a l  r ;
% g lo b a l  Co; 
g l o b a l  t ;
% g lo b a l  a;
%Load t x t  f i l e
f i l e n a m e  = i n p u t ( ' E n t e r  f i l e  name: ' , ' s ' ) ;
I  = l o a d ( f i l e n a m e ) ;
%Required u s e r  i n p u t  v a lu e s
%Co = i n p u t ( ' E n t e r  v a lu e  o f  Co: ' ) ;
t  = i n p u t ( ' E n t e r  v a l u e  o f  t  ( s e c ) :  ' ) ;
%Def ined v a lu e s
10 = I ;




a = ( ( V * 3 ) / ( 4 * p i ) ) A ( 1 / 3 ) ;
DO = 4E-4 ;
xmax
oII
% C a lc u la te  FWHM & SD 
w i d t h  = f w h m ( I ( : , 1 ) , I ( : , 2 ) ) ;
SD = w i d t h / ( 2 * s q r t ( 2 * ( l o g ( 2 ) ) ) ) ;  
SD1 = ( 0 . 5 * w id th )+ S D ;
SD2 = ( 0 . 5 * w i d t h ) + (2 *S D ) ;
SD3 = ( 0 . 5 * w i d t h ) + (3 *S D ) ;
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%Center d i s t a n c e  v a lu e s  a b o u t  ze ro  
[M,N] = m a x (1 0 ) ;  
dmax = 1 0 (N ( 1 , 2 ) ,  1) ;
r  = I ( : , l )  -  ( d m a x + lE -1 0 ) ; %cannot have r  = 0 b / c  NaN w i l l  be 
r e t u r n e d  and o p t i m i z a t i o n  t e r m i n a t e d
% C a lc u la te  window 
p l o t ( r , I ( : , 2 ) ) ;  h o l d  on;
p l o t ( x m a x + S D l , 0 : 2 0 0 0 / '  r  : ' , x m a x - S D l ,0 : 2 0 0 0 , '  r  : '  ) ;  
p lo t ( x m a x + S D 2 , 0 : 2 0 0 0 ,' b: ' , xmax-SD2,0 : 2 0 0 0 ,'b:' ) ;  
p lo t ( x m a x + S D 3 , 0 : 2 0 0 0 , '  g : ' , xmax-SD3,0 : 2 0 0 0 , '  g : '  ) ;  
h o l d  o f f ;
%d = I  ( : , 1 ) ;
d i s p ( ' S e l e c t  a l e f t  p o i n t  and r i g h t  p o i n t  t o  d e f i n e  t h e  
w i n d o w . 1) ;
I  = I  ( : / 2 ) ;
[Wl,W2]=ginput(2); 
low=find(r>Wl(1),1, 1 first1); 
high=find(r<Wl(2),1,1last1);
r  = r ( l o w : h i g h ) ;
I  = I  ( l o w : h i g h ) ; 
p l o t ( r , I )
% p l o t ( r ( l o w : h i g h ) , I ( l o w : h i g h ) )
% C a lc u la te  b a ckg ro u n d  
p l o t ( 1 0 ) ;
d i s p ( ' S e l e c t  p o i n t s  t o  c a l c u l a t e  a b a ckg ro u n d  a v e ra g e .  P ress  
ENTER key when d o n e . 1) ;
[ p x , q y ]  = g i n p u t ;  
b a ck  = m e a n (q y ) ;
% S igna l  i n t e n s i t y  i s  d e f i n e d  by  re m o v in g  u s e r - d e f i n e d  b a ckg ro u n d  
s i g n a l
1 = 1 -  b a ck ;
%D = l s q c u r v e f i t ( ' C r a n k 1, DO, r , I )  ;
[ D , r e s n o r m , r e s i d u a l , e x i t f l a g , o u t p u t , l a m b d a , J ]  = 
l s q c u r v e f i t ( ' C r a n k 1, D O , r , I ) ;
C = C r a n k ( D , r ) ;
D
% C a lc u la te  c o e f f i c i e n t  o f  d e t e r m i n a t i o n  
MeanY = m e a n ( I ) ;
R2 = 1 - ( s u m ( ( I - C ) . A2 ) / s u m ( ( I - M e a n Y ) . A2 ) )
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% Plo t  o b s e rv e d  and p r e d i c t e d  r e s u l t s  on t h e  same g ra ph
p l o t ( r , I , ' k -  ' ,  r ,  C , 1k : ' )
l e g e n d ( 1 O b s e rv e d ' , '  P r e d i c t e d 1)
x l a b e l ( 1 D is t a n c e  f ro m  c e n t e r  (mm)1)
y l a b e l ( ' C o n c e n t r a t i o n  ( AU) ' )
% Use NLPREDCI t o  f i n d  c o n f i d e n c e  i n t e r v a l s  on t h e  m o d e l ' s  
re s p o n s e
[ y p r e d , d e l t a ] = n l p r e d c i ( ' C r a n k ' , r , D , r e s i d u a l , ' j a c o b i a n ' , J) ;
C l  = m a x ( d e l t a ) ;
% P l o t  t h e  c o n f i d e n c e  i n t e r v a l s  w i t h  t h e  o r i g i n a l  d a ta  —  y p re d  &
C a re  t h e  SAME!
f i g u r e
p l o t  ( r , y p r e d )
h o l d  on
p l o t ( r , I , ' + r ' )
p l o t ( r , y p r e d  + C l , ' — g ' )
p l o t ( r , y p r e d  -  C l , ' — g ' )
%Output m a t r i x
OUTPUT = [ t ,  V, b a ck ,  m i n ( r ) ,  m a x ( r ) ,  D, R2, C l ]  
c l i p b o a r d ( ' c o p y ' , OUTPUT);
Function for passive diffusion equation from Crank (1975) used in Optimization code
f u n c t i o n  F = C r a n k ( D , r )
global t
% Def ined  v a lu e s  
Co = 4148;
V = 30;
a = ( (V*3)/ (4*pi))A (1/3);
DO = 4 E -4 ;
F = ((1/2).*(Co).*(erf((a-
r)./(2.*(sqrt(D.*t))))+(erf((a+r)./(2.*(sqrt(D.*t)>>)))>- 
((Co./r).*(sqrt((D.*t)./pi)) . * ((exp((-((a-r).A2))./(4.*D.*t))- 
(exp( (-((a+r).A2))./(4.*D.*t))))));
